var title_f40_48_41728="Eval incompatible crossmatch";
var content_f40_48_41728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Laboratory evaluation and management of incompatible crossmatch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 524px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41728=[""].join("\n");
var outline_f40_48_41728=null;
var title_f40_48_41729="Patient information: Caring for an uncircumcised penis (The Basics)";
var content_f40_48_41729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16329\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/55/23423\">",
"         Uncircumcised penis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/52/15183\">",
"          Circumcised penis",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/29/40401\">",
"         Patient information: Balanitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/36/29249\">",
"         Patient information: Circumcision in baby boys (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/5/1107\">",
"         Patient information: Circumcision in baby boys (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Caring for an uncircumcised penis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/caring-for-an-uncircumcised-penis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1707322\">",
"      <span class=\"h1\">",
"       What does an uncircumcised penis look like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A penis that is uncircumcised (not circumcised) has extra skin that covers its tip (",
"      <a class=\"graphic graphic_picture graphicRef69361 \" href=\"mobipreview.htm?22/55/23423\">",
"       picture 1",
"      </a>",
"      ). This extra skin is called the &ldquo;foreskin.&rdquo; It protects the tip of the penis. When a baby boy is circumcised, it means he had a procedure to remove the foreskin (",
"      <a class=\"graphic graphic_picture graphicRef74651 \" href=\"mobipreview.htm?14/52/15183\">",
"       picture 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      After birth, a baby boy&rsquo;s foreskin is stuck in place and can&rsquo;t be pulled back over the tip of the penis. This is normal. Over time, the foreskin will loosen up. But it can take years until the foreskin can be pulled back completely over the tip of the penis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1707329\">",
"      <span class=\"h1\">",
"       How do I take care of my baby&rsquo;s uncircumcised penis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Until your baby is 6 months old, do",
"      <strong>",
"       not",
"      </strong>",
"      try to pull the foreskin back over the penis. Instead, to take care of your baby&rsquo;s penis, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash it during bath time with a gentle, nonirritating soap",
"       </li>",
"       <li>",
"        Change your baby&rsquo;s diaper often so that he doesn&rsquo;t get a diaper rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your baby is 6 months old, you can start to gently pull back on the foreskin when you clean the penis. It&rsquo;s important to pull the foreskin back only as far as it goes and not force it any further. As you pull the foreskin back, gently clean and then dry the skin underneath. When you are done, make sure to return the foreskin to its normal place so that it covers the tip of the penis.",
"     </p>",
"     <p>",
"      When your son is older and can clean himself, you can teach him how to take care of his foreskin and penis. Each time he cleans himself, he should pull the foreskin back, clean and dry the skin underneath, and then return it to its normal place.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1707336\">",
"      <span class=\"h1\">",
"       What problems can happen in an uncircumcised penis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen. Some are normal and do not usually need to be treated. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        White lumps that collect under the foreskin",
"       </li>",
"       <li>",
"        Swelling of the tip of the penis during urination that lasts only for a short time",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other conditions are more serious and usually need treatment. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Infections of the foreskin or penis",
"       </li>",
"       <li>",
"        Infections of the urinary tract",
"       </li>",
"       <li>",
"        The foreskin getting stuck so that it can&rsquo;t return to its normal place",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1707343\">",
"      <span class=\"h1\">",
"       When should I call my son&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call the doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your son has pain (or seems to be in pain) when he urinates",
"       </li>",
"       <li>",
"        His penis is swollen, red, or bleeding",
"       </li>",
"       <li>",
"        His stream of urine dribbles or is not straight (goes off to 1 side)",
"       </li>",
"       <li>",
"        His foreskin gets stuck and can&rsquo;t return to its normal place",
"       </li>",
"       <li>",
"        You are worried about your son&rsquo;s penis",
"       </li>",
"       <li>",
"        You have questions about how to take care of your son&rsquo;s penis",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1707350\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/36/29249?source=see_link\">",
"       Patient information: Circumcision in baby boys (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/29/40401?source=see_link\">",
"       Patient information: Balanitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/5/1107?source=see_link\">",
"       Patient information: Circumcision in baby boys (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/48/41729?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16329 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41729=[""].join("\n");
var outline_f40_48_41729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1707322\">",
"      What does an uncircumcised penis look like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1707329\">",
"      How do I take care of my baby&rsquo;s uncircumcised penis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1707336\">",
"      What problems can happen in an uncircumcised penis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1707343\">",
"      When should I call my son&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1707350\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/55/23423\">",
"      Uncircumcised penis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/52/15183\">",
"       Circumcised penis",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/29/40401?source=related_link\">",
"      Patient information: Balanitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/5/1107?source=related_link\">",
"      Patient information: Circumcision in baby boys (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/36/29249?source=related_link\">",
"      Patient information: Circumcision in baby boys (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41730="Diagnosis of sideroblastic anemia";
var content_f40_48_41730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 635px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnostic evaluation of a patient with sideroblastic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 615px; height: 639px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mean corpuscular volume is most accurate before the patient has received any transfusion. Mutation analysis where the causative gene is known provides definitive diagnosis and facilitates detection of affected or gene carrier relatives.",
"    <div class=\"footnotes\">",
"     * Microcytic hypochromic red cells may be present in the blood smear in many, but not all, of these disease types.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Typically presents in infancy or childhood.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41730=[""].join("\n");
var outline_f40_48_41730=null;
var title_f40_48_41731="Articaine and epinephrine: Patient drug information";
var content_f40_48_41731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Articaine and epinephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/52/3911?source=see_link\">",
"     see \"Articaine and epinephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Articadent&trade;;",
"     </li>",
"     <li>",
"      Orabloc&trade;;",
"     </li>",
"     <li>",
"      Septocaine&reg; with epinephrine 1:100,000;",
"     </li>",
"     <li>",
"      Septocaine&reg; with epinephrine 1:200,000;",
"     </li>",
"     <li>",
"      Zorcaine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F730244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Astracaine&reg; with epinephrine 1:200,000;",
"     </li>",
"     <li>",
"      Astracaine&reg; with epinephrine forte 1:100,000;",
"     </li>",
"     <li>",
"      Posicaine N;",
"     </li>",
"     <li>",
"      Posicaine SP;",
"     </li>",
"     <li>",
"      Septanest&reg; N;",
"     </li>",
"     <li>",
"      Septanest&reg; SP;",
"     </li>",
"     <li>",
"      Ultracaine&reg; DS;",
"     </li>",
"     <li>",
"      Ultracaine&reg; DS Forte;",
"     </li>",
"     <li>",
"      Zorcaine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before dental care to numb the area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to articaine, epinephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11571 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-8A237B75EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41731=[""].join("\n");
var outline_f40_48_41731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136653\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730244\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025531\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025533\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025532\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025536\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025537\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025538\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025535\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025539\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025540\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/52/3911?source=related_link\">",
"      Articaine and epinephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41732="Baclofen: Patient drug information";
var content_f40_48_41732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Baclofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     see \"Baclofen: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7878?source=see_link\">",
"     see \"Baclofen: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gablofen&reg;;",
"     </li>",
"     <li>",
"      Lioresal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Baclofen&reg;;",
"     </li>",
"     <li>",
"      Ava-Baclofen;",
"     </li>",
"     <li>",
"      Dom-Baclofen;",
"     </li>",
"     <li>",
"      Lioresal&reg;;",
"     </li>",
"     <li>",
"      Lioresal&reg; D.S.;",
"     </li>",
"     <li>",
"      Lioresal&reg; Intrathecal;",
"     </li>",
"     <li>",
"      Med-Baclofen;",
"     </li>",
"     <li>",
"      Mylan-Baclofen;",
"     </li>",
"     <li>",
"      Novo-Baclofen;",
"     </li>",
"     <li>",
"      Nu-Baclo;",
"     </li>",
"     <li>",
"      PHL-Baclofen;",
"     </li>",
"     <li>",
"      PMS-Baclofen;",
"     </li>",
"     <li>",
"      ratio-Baclofen;",
"     </li>",
"     <li>",
"      Riva-Baclofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shot: Do not stop taking this drug all of a sudden. Unsafe side effects may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691648",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop hiccups.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bladder spasms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692089",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spasms in patients with MS (multiple sclerosis) or spinal cord disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to baclofen or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with rest, PT (physical therapy), pain drugs, and other therapies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 35 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11129 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41732=[""].join("\n");
var outline_f40_48_41732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138898\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016975\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016977\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016976\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016981\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016982\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016984\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016979\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016980\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016985\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016986\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=related_link\">",
"      Baclofen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7878?source=related_link\">",
"      Baclofen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41733="JXG solitary lesion";
var content_f40_48_41733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69122%7EDERM%2F81386%7EDERM%2F59377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69122%7EDERM%2F81386%7EDERM%2F59377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical solitary lesion on the abdomen of an infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 226px; height: 159px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single nodule of juvenile xanthogranuloma in the nasolabial fold of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single nodule of juvenile xanthogranuloma on the chin of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41733=[""].join("\n");
var outline_f40_48_41733=null;
var title_f40_48_41734="Hypercalcemia of malignancy";
var content_f40_48_41734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypercalcemia of malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41734/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41734/contributors\">",
"     Mara J Horwitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41734/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41734/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41734/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41734/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/48/41734/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is relatively common in patients with cancer, occurring in approximately 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the most common cause of hypercalcemia in the inpatient setting. It occurs in patients with both solid tumors and hematologic malignancies. The most common cancers associated with hypercalcemia are breast and lung cancer and multiple myeloma. Malignancy is often evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy often have a poor prognosis.",
"   </p>",
"   <p>",
"    Hypercalcemia in patients with cancer is primarily due to increased bone resorption and release of calcium from bone. There are three major mechanisms by which this can occur: osteolytic metastases with local release of cytokines (including osteoclast activating factors); tumor secretion of parathyroid hormone-related protein (PTHrP); and tumor production of 1,25-dihydroxyvitamin D (calcitriol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These mechanisms will be reviewed here.",
"   </p>",
"   <p>",
"    Bisphosphonates are the most commonly used agents to treat hypercalcemia of malignancy. In addition, bisphosphonate therapy may prevent skeletal complications and perhaps improve survival in patients with multiple myeloma or breast cancer. These issues are all addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OSTEOLYTIC METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteolytic metastases account for approximately 20 percent of cases of hypercalcemia of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/4\">",
"     4",
"    </a>",
"    ]. Induction of local osteolysis by tumor cells is common with some solid tumors that are metastatic to bone and with multiple myeloma, but it is less common with lymphoma and leukemia (",
"    <a class=\"graphic graphic_table graphicRef74189 \" href=\"mobipreview.htm?0/16/268\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/1,2,5,6\">",
"     1,2,5,6",
"    </a>",
"    ]. The solid tumor that most often produces hypercalcemia by this mechanism is breast cancer. The bone destruction observed in osteolytic metastases is primarily mediated by osteoclasts and is not a direct effect of tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Instead, tumors produce many factors that stimulate osteoclast production and action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer cells in bone express parathyroid-related protein (PTHrP) more frequently than in soft tissue sites or in the primary tumor. Locally produced PTHrP causes osteolysis that can be ameliorated by administration of anti-PTHrP antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/9\">",
"     9",
"    </a>",
"    ]. This occurs in the absence of high serum PTHrP concentrations. In other patients with breast cancer, bone metastases, and hypercalcemia, serum PTHrP is elevated, suggesting a systemic effect as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'PTH-related protein'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Locally produced PTHrP increases expression of receptor activator of nuclear factor kappa B ligand (RANKL) in bone. RANKL contributes to the development of hypercalcemia by binding to receptor activator of nuclear factor kappa B (RANK) on the surface of osteoclast precursors. The",
"    <span class=\"nowrap\">",
"     RANKL/RANK",
"    </span>",
"    interaction results in activation, migration, differentiation, and fusion of hematopoietic cells of the osteoclast lineage to begin the process of resorption. In addition, cytokines such as IL-6, IL-8, IL-1, and VEGF are secreted by breast cancer cells and may contribute to the effects of PTHrP on bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=see_link&amp;anchor=H15#H15\">",
"     \"Mechanisms of bone metastases\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with breast cancer and extensive skeletal metastases, the administration of an antiestrogen (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ) or high-dose estrogen can lead to hypercalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/11\">",
"     11",
"    </a>",
"    ]. The presumed mechanism is release of bone resorbing factors from the tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia in multiple myeloma and some cases of lymphoma where there is bone marrow infiltration by tumor has been ascribed to the release of osteoclast activating factors by the tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/13\">",
"     13",
"    </a>",
"    ]. Osteoclast-induced bone resorption may occur in discrete focal areas (lytic lesions) or throughout the skeleton. The high rate of bone resorption is associated with an absence of osteoblast-mediated bone formation, resulting in diffuse bone loss. The uncoupling of bone resorption and formation results from paracrine factors, which enhance osteoclast formation and activity and inhibit the capacity for marrow stromal cells to differentiate into osteoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/13\">",
"     13",
"    </a>",
"    ]. In multiple myeloma, various studies have implicated interleukin (IL)-6, RANKL, macrophage inflammatory protein 1a, osteoprotegerin, and IL-3 as factors contributing to the development of lytic bone disease and hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=see_link&amp;anchor=H8#H8\">",
"     \"Mechanisms of bone metastases\", section on 'Multiple myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PTH-RELATED PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of hypercalcemia in patients with nonmetastatic solid tumors and in some patients with non-Hodgkin lymphoma is secretion of parathyroid-related hormone (PTHrP); this condition, also called humoral hypercalcemia of malignancy (HHM), accounts for up to 80 percent of patients with hypercalcemia of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/4,14-16\">",
"     4,14-16",
"    </a>",
"    ]. Patients with HHM most often have squamous cell carcinomas (lung, head, and neck), renal, bladder, breast, or ovarian carcinomas (",
"    <a class=\"graphic graphic_table graphicRef74189 \" href=\"mobipreview.htm?0/16/268\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    PTHrP is a normal gene product expressed in a wide variety of neuroendocrine, epithelial, and mesoderm-derived tissues. Thus, in addition to patients with solid tumors, those with non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ], chronic myeloid leukemia (blast phase) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/18\">",
"     18",
"    </a>",
"    ], and adult T-cell leukemia-lymphoma may have PTHrP-induced hypercalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/15,19,20\">",
"     15,19,20",
"    </a>",
"    ]. Tumor necrosis factor-beta also may contribute in some patients with adult T-cell leukemia-lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9945?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with HHM, secretion of endogenous parathyroid hormone (PTH) itself is suppressed by the PTHrP-mediated hypercalcemia. Thus, serum intact PTH concentrations are typically suppressed or very low in patients with humoral hypercalcemia of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/1,2,14\">",
"     1,2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Purification of PTHrP has revealed some homology with PTH, particularly at the amino-terminal end, at which the first 13 amino acids are almost identical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result of this close homology with PTH, PTHrP binds to the same PTH-1 receptor as does PTH and thus activates similar post-receptor pathways. This accounts for the ability of PTHrP to simulate some of the actions of PTH, including increases in bone resorption and distal tubular calcium reabsorption, and inhibition of proximal tubular phosphate transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/16,23-25\">",
"     16,23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Structural divergence after the first 13 amino acids of the molecule accounts for its immunologic distinctiveness from PTH. PTHrP is less likely than PTH to stimulate 1,25-dihydroxyvitamin D production (the serum concentrations of which are normal or low in HHM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/16,26-29\">",
"     16,26-29",
"    </a>",
"    ]. As a result, PTHrP does not increase intestinal calcium absorption. In patients with HHM, there is an uncoupling of bone resorption and formation, which results in a large flux of calcium from bone into the circulation. This, in combination with the reduced ability of the kidney to clear calcium, results in the striking hypercalcemia that occurs in HHM. Thus, hypercalcemia in HHM is due to the combined effects of PTHrP on kidney and bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/16,23,30\">",
"     16,23,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of PTHrP in normal physiology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humoral hypercalcemia should be suspected as the cause of hypercalcemia in any patient with a solid tumor in the absence of bony metastases. It should also be suspected in patients with otherwise unexplained hypercalcemia and a low serum PTH concentration. Patients with PTHrP-induced hypercalcemia related to cancer typically have advanced disease and a poor prognosis. A nonmalignant disorder is more likely in a patient who has chronic hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of humoral hypercalcemia of malignancy (HHM) can be confirmed by demonstrating a high serum concentration of PTHrP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/14\">",
"     14",
"    </a>",
"    ]. This finding is present in most hypercalcemic patients with solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/14,22\">",
"     14,22",
"    </a>",
"    ]. However, this assay is often not necessary for diagnosis since most patients have clinically apparent malignancy.",
"   </p>",
"   <p>",
"    Serum PTHrP concentrations are low (undetectable in most assays) in patients with primary hyperparathyroidism and in normal subjects. Patients with cancer who are normocalcemic may have slightly high concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/31\">",
"     31",
"    </a>",
"    ]. The results are similar in these groups whether serum PTHrP is measured using assays that detect primarily amino-terminal or carboxyl-terminal epitopes of PTHrP. The main difference in the two types of assays is that patients with renal insufficiency may have high serum PTHrP values when it is measured using a carboxy-terminal assay, because of accumulation of carboxy-terminal fragments of PTHrP.",
"   </p>",
"   <p>",
"    In addition to its potential role in diagnosis, measurements of serum PTHrP levels in patients with tumor-induced hypercalcemia can provide information regarding prognosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is a useful tumor marker for assessing the response to treatment of the tumor.",
"     </li>",
"     <li>",
"      It may predict the response to bisphosphonates. Serum PTHrP concentrations above 12",
"      <span class=\"nowrap\">",
"       pmol/L",
"      </span>",
"      are frequently associated with both a lesser reduction in hypercalcemia and with recurrence of hypercalcemia within 14 days of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. While the prognosis of cancer-associated hypercalcemia is generally poor, those who become normocalcemic with bisphosphonate therapy have a significantly better, although still short survival (53 versus 19 days in one study) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of hypercalcemia\", section on 'Pamidronate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with high serum PTHrP concentrations appear to have shorter median survival times [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/33,35\">",
"       33,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, no treatment that specifically inhibits PTHrP release is available. In animals, acutely lowering PTHrP action (via passive immunization) reduces serum calcium concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/36\">",
"     36",
"    </a>",
"    ]. Administration of noncalcemic vitamin D analogs can decrease PTHrP release in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/20\">",
"     20",
"    </a>",
"    ]; whether these agents will prove to be effective in patients is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     1,25-DIHYROXYVITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased production of 1,25-dihydroxyvitamin D (calcitriol) is the cause of almost all cases of hypercalcemia in Hodgkin lymphoma and approximately one-third of cases in non-Hodgkin lymphoma (",
"    <a class=\"graphic graphic_table graphicRef74189 \" href=\"mobipreview.htm?0/16/268\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. An occasional patient with Hodgkin lymphoma, however, has hypercalcemia due to PTHrP, as do some with non-Hodgkin lymphoma, as stated above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/14,17,31\">",
"     14,17,31",
"    </a>",
"    ]. 1,25-dihydroxyvitamin D-induced hypercalcemia has also been described in patients with ovarian dysgerminoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/37\">",
"     37",
"    </a>",
"    ] and lymphomatoid",
"    <span class=\"nowrap\">",
"     granulomatosis/angiocentric",
"    </span>",
"    lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/38\">",
"     38",
"    </a>",
"    ]; the latter finding is consistent with the frequent association of hypercalcemia with chronic granulomatous diseases, such as sarcoidosis and tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In normal subjects, the conversion of 25-hydroxyvitamin D (calcidiol) to 1,25-dihydroxyvitamin D (calcitriol, the most active metabolite of vitamin D) occurs via a 1-hydroxylase in the kidney that is under the physiologic control of parathyroid hormone (PTH) and the serum phosphate concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .) Hypercalcemia should suppress the release of PTH and therefore the production of 1,25-dihydroxyvitamin D (1,25 D). The lack of suppression of 1,25 D production in lymphoma is due to PTH-independent extrarenal production of 1,25 D from 25-hydroxyvitamin D by malignant lymphocytes, macrophages, or both.",
"   </p>",
"   <p>",
"    Increased intestinal calcium absorption induced by high serum 1,25 D concentrations is the primary abnormality, although a 1,25 D-induced increase in bone resorption may play a contributory role. Hypercalcemia induced by 1,25 D usually responds to glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ECTOPIC PTH SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few patients with ectopic secretion of PTH have been described; among the tumors were an ovarian carcinoma, small cell and squamous cell lung carcinomas, a primitive neuroectodermal tumor, thyroid papillary carcinoma, metastatic rhabdomyosarcoma, and pancreatic malignancy (",
"    <a class=\"graphic graphic_table graphicRef74189 \" href=\"mobipreview.htm?0/16/268\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/39-45\">",
"     39-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COEXISTING PRIMARY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a higher incidence of cancer in patients with primary hyperparathyroidism and of primary hyperparathyroidism in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Thus, serum PTH should be measured in hypercalcemic patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/48\">",
"     48",
"    </a>",
"    ]. If serum PTHrP and PTH concentrations are both high, then coexisting primary hyperparathyroidism is probably present as well; if serum PTH is elevated and PTHrP is suppressed, then primary hyperparathyroidism is probably the sole cause for the hypercalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41734/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is not uncommon in patients with malignancy, and it is associated with a poor prognosis. The most common tumors that cause hypercalcemia are breast cancer, multiple myeloma, lymphoma, and squamous cell cancers (",
"    <a class=\"graphic graphic_table graphicRef74189 \" href=\"mobipreview.htm?0/16/268\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are three major mechanisms by which hypercalcemia of malignancy can occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteolytic metastases with local release of cytokines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Osteolytic metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor secretion of parathyroid hormone-related protein (PTHrP). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'PTH-related protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor production of 1,25-dihydroxyvitamin D. (See",
"      <a class=\"local\" href=\"#H7\">",
"       '1,25-dihyroxyvitamin D'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypercalcemia in patients with osteolytic metastases is primarily due to increased bone resorption and release of calcium from bone, whereas hypercalcemia in patients with tumors secreting PTHrP is due to both increased bone resorption and distal renal tubular calcium reabsorption. In patients with tumoral production of 1,25-dihydroxyvitamin D, hypercalcemia is the result of a combination of increased bone resorption and intestinal calcium absorption.",
"   </p>",
"   <p>",
"    The treatment of hypercalcemia of malignancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/1\">",
"      Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/2\">",
"      Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/3\">",
"      Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/4\">",
"      Horwitz, MJ, Stewart, AF. Hypercalcemia associated with malignancy. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society of Bone and Mineral Research. 2006; 31:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/5\">",
"      Francini G, Petrioli R, Maioli E, et al. Hypercalcemia in breast cancer. Clin Exp Metastasis 1993; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/6\">",
"      Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/7\">",
"      Quinn JM, Matsumura Y, Tarin D, et al. Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest 1994; 71:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/8\">",
"      Taube T, Elomaa I, Blomqvist C, et al. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/9\">",
"      Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/10\">",
"      Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991; 73:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/11\">",
"      Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981; 47:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/12\">",
"      Valentin-Opran A, Eilon G, Saez S, Mundy GR. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells. J Clin Invest 1985; 75:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/13\">",
"      Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/14\">",
"      Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/15\">",
"      Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994; 79:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/16\">",
"      Horwitz MJ, Tedesco MB, Sereika SM, et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003; 88:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/17\">",
"      Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/18\">",
"      Seymour JF, Grill V, Martin TJ, et al. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein. Leukemia 1993; 7:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/19\">",
"      Nakamura Y, Bando H, Shintani Y, et al. Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinol (Copenh) 1992; 127:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/20\">",
"      Inoue D, Matsumoto T, Ogata E, Ikeda K. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J Biol Chem 1993; 268:16730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/21\">",
"      Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood 1991; 77:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/22\">",
"      Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990; 322:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/23\">",
"      Rizzoli R, Ferrari SL, Pizurki L, et al. Actions of parathyroid hormone and parathyroid hormone-related protein. J Endocrinol Invest 1992; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/24\">",
"      Fraher LJ, Hodsman AB, Jonas K, et al. A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 1992; 75:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/25\">",
"      Esbrit P, Egido J. The emerging role of parathyroid hormone-related protein as a renal regulating factor. Nephrol Dial Transplant 2000; 15:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/26\">",
"      Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993; 76:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/27\">",
"      Schweitzer DH, Hamdy NA, Fr&ouml;lich M, et al. Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol (Oxf) 1994; 41:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/28\">",
"      Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996; 81:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/29\">",
"      Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 2005; 20:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/30\">",
"      Syed MA, Horwitz MJ, Tedesco MB, et al. Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 2001; 86:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/31\">",
"      Henderson JE, Shustik C, Kremer R, et al. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 1990; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/32\">",
"      Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/33\">",
"      Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/34\">",
"      Ling PJ, A'Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 1995; 72:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/35\">",
"      Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994; 78:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/36\">",
"      Henderson J, Bernier S, D'Amour P, Goltzman D. Effects of passive immunization against parathyroid hormone (PTH)-like peptide and PTH in hypercalcemic tumor-bearing rats and normocalcemic controls. Endocrinology 1990; 127:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/37\">",
"      Hibi M, Masahito H, Hara F, et al. 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol 2008; 25:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/38\">",
"      Scheinman SJ, Kelberman MW, Tatum AH, Zamkoff KW. Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci 1991; 301:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/39\">",
"      Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989; 68:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/40\">",
"      Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990; 323:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/41\">",
"      Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993; 76:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/42\">",
"      Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, et al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 1996; 81:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/43\">",
"      Wong K, Tsuda S, Mukai R, et al. Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine 2005; 27:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/44\">",
"      VanHouten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 2006; 91:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/45\">",
"      Vacher-Coponat H, Opris A, Denizot A, et al. Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. Nephrol Dial Transplant 2005; 20:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/46\">",
"      Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995; 71:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/47\">",
"      Strodel WE, Thompson NW, Eckhauser FE, Knol JA. Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol 1988; 37:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41734/abstract/48\">",
"      Casez J, Pfammatter R, Nguyen Q, et al. Diagnostic approach to hypercalcemia: relevance of parathyroid hormone and parathyroid hormone-related protein measurements. Eur J Intern Med 2001; 12:344.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 842 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41734=[""].join("\n");
var outline_f40_48_41734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OSTEOLYTIC METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PTH-RELATED PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      1,25-DIHYROXYVITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ECTOPIC PTH SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COEXISTING PRIMARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/842\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/842|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/16/268\" title=\"table 1\">",
"      Cancers associated with hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41735="Overview of the principles of medical consultation and perioperative medicine";
var content_f40_48_41735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the principles of medical consultation and perioperative medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     Steven L Cohn, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     David S Macpherson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41735/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/48/41735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internists are often asked to evaluate a patient prior to surgery. The medical consultant may be seeing the patient at the request of the surgeon, or may be the primary care physician assessing the patient prior to consideration of a surgical referral. The goals of this evaluation are to determine the risk to the patient of the proposed procedure and to minimize known risks. These goals are achieved by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identifying unrecognized comorbid disease and risk factors for medical complications of surgery",
"     </li>",
"     <li>",
"      Optimizing the preoperative medical condition",
"     </li>",
"     <li>",
"      Recognizing and treating potential complications",
"     </li>",
"     <li>",
"      Working effectively as a member of the preoperative team (including surgical and anesthesia colleagues)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Internists and hospitalists leaving training sometimes feel unprepared to consult on patients requiring surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, it is worthwhile to develop an optimal consultation technique since this will increase the chance that the recommendations of the consultant are followed.",
"   </p>",
"   <p>",
"    The general principles of medical consultation, including techniques that optimize the interaction between referring physicians and consultants, and effects of anesthesia, are reviewed here. Specific issues in preoperative consultation (such as evaluating pulmonary risk, cardiovascular risk, etc) and perioperative medication management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link\">",
"     \"Perioperative medication management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECT ON SURGICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigators have studied whether internist care of surgical patients is beneficial. These studies have shown that internists identify medical conditions that are related to surgical outcome and often recommend interventions for these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In addition, consultants occasionally cancel or delay surgery so that medical conditions can be optimized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Physician satisfaction with comanagement arrangements is high when measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies report conflicting findings regarding the effect of medical consultation on utilization or cost measures. Two cohort studies demonstrated a decrease in length of stay when an internist routinely cared for patients after thoracic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/9\">",
"     9",
"    </a>",
"    ] or hip fracture surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/10\">",
"     10",
"    </a>",
"    ], while another showed similar or increased costs and length of stay for consulted patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/11\">",
"     11",
"    </a>",
"    ]. Another retrospective cohort study demonstrated a slight reduction in overall hospital costs, but no change in length of stay, after implementation of a hospitalist comanagement service for neurosurgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, it is unclear if medical consultation has an impact on perioperative mortality. In the cohort of neurosurgical patients, no mortality difference was observed after implementation of a hospitalist comanagement service [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/8\">",
"     8",
"    </a>",
"    ]. In another large retrospective cohort study of patients undergoing elective intermediate to high risk surgery, analysis of matched pairs found that medical consultation was associated with slightly higher 30 day and one year mortality rates and longer average length of stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients receiving medical consultation had a higher disease burden, which was adjusted in multivariable analysis. However, differences in risk between those selected for medical consultation and those not selected may account for the difference in mortality rates. The association of medical consultation with mortality was small, and further studies are needed to determine the impact of medical consultation on surgical outcomes.",
"   </p>",
"   <p>",
"    Overall, strong evidence showing clear improvements in resource use or patient outcomes is lacking. Nevertheless, the practice of medical consultation is widespread and, assuming consultants make evidence-based recommendations that improve surgical outcomes, it is reasonable to infer that consultation will improve the care of the surgical patient if consultative recommendations are implemented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective and satisfactory medical consultation can be performed when the consultant follows some general principles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Determine the question and respond to it.",
"     </li>",
"     <li>",
"      Establish the urgency of the consultation and provide a timely response.",
"     </li>",
"     <li>",
"      \"Look for yourself\"; confirm the history and physical examination and check test results.",
"     </li>",
"     <li>",
"      Be as brief as appropriate; be definitive and limit the number of recommendations.",
"     </li>",
"     <li>",
"      Be specific, including medication details.",
"     </li>",
"     <li>",
"      Provide contingency plans; anticipate potential problems and questions.",
"     </li>",
"     <li>",
"      Honor thy turf; don't steal other physician's patients.",
"     </li>",
"     <li>",
"      Teach with tact; consult, don't insult.",
"     </li>",
"     <li>",
"      Talk is cheap and effective; direct verbal communication is crucial.",
"     </li>",
"     <li>",
"      Follow-up to ensure that recommendations are followed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Needs of the requesting physician",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Reasons for consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consultation is a request made to another physician to give his or her opinion on the diagnosis or management of a particular patient. The requesting clinician may seek consultation for surgical risk assessment, approval for anesthesia or surgery, advice on diagnostic problems or management issues in the perioperative period, confirmation of a plan or assessment and reassurance, or documentation for medical legal reasons. The role of the consultant should be defined through communication with the referring physician. Surgeons more often desire \"comanagement\" by internists in which the internist is asked to assume the management of specific aspects of the patient's care including order writing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/14\">",
"     14",
"    </a>",
"    ]. However, unless a standing arrangement exists for comanagement, the surgeon needs to explicitly communicate this to the consultant.",
"   </p>",
"   <p>",
"    Of the nine ethical principles pertaining to consultation published by the American Medical Association (AMA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/15\">",
"     15",
"    </a>",
"    ], three pertain to the referring physician:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consultations are indicated on request, in doubtful or difficult cases, or when they enhance the quality of medical care.",
"     </li>",
"     <li>",
"      Consultations are primarily for the patient's benefit.",
"     </li>",
"     <li>",
"      A consult request should be sent to the consulting physician unless a verbal description of the case has already been given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effective communication is the foundation underlying the art of medical consultation; the manner in which the question or information is phrased can influence the consultant's response. The \"routine\" consult request, for example, will generate a different response than the request for specific advice on the management of preoperative congestive heart failure.",
"   </p>",
"   <p>",
"    A requesting physician should state clearly the questions to be answered by the consultant; it is the consultant's role to understand the reason for the consultation. However, this is often not the case. In one study, for example, disagreement occurred between the primary physician and the consultant about the primary reason for consultation in 14 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16\">",
"     16",
"    </a>",
"    ]. A study of preoperative cardiology consultations noted that over half of the consult requests were for \"evaluation,\" 40 percent for \"medical clearance,\" and no specific reason clarified for 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/17\">",
"     17",
"    </a>",
"    ]. In another report of preoperative consultations in diabetic patients, no specific question was asked in 24 percent, and consultants ignored explicit questions in another 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/18\">",
"     18",
"    </a>",
"    ]. Given the high frequency of misunderstanding between consultants and referring physicians, direct communication is important and likely will prevent misinterpretation.",
"   </p>",
"   <p>",
"    Efforts should be made to discuss potentially controversial recommendations with the team; inflammatory notes should not be left in the chart. Given the high frequency of misunderstanding between consultants and referring physicians, direct communication is important and likely will prevent misinterpretation.",
"   </p>",
"   <p>",
"    Traditionally, consultative advice should be specific to the question asked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16\">",
"     16",
"    </a>",
"    ]. If the consultant identifies areas of concern distinct from the original reason for the consult, permission from the requesting physician should be sought before discussing this in the consult note. However, only 41 percent of surgeons in one survey believed that internal medicine consultants should limit themselves to a specific question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Implications of clearing a patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;A commonly stated purpose of a preoperative consultation request is to \"clear\" a patient for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. This statement may incorrectly imply that the procedure carries no risk for the particular patient, when all patients are potentially at some risk when they undergo anesthesia and surgery. Thus, a consultant should avoid use of the phrase \"cleared for surgery\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instead, the consultant seeks factors that might put the patient at higher than average risk and proposes plans to reduce this risk. Risks are specific to the individual patient, the type of procedure proposed, and the type of anesthesia selected. If no such risks are present, the consultant's final statement is that the patient is at average risk for the proposed surgery.",
"   </p>",
"   <p>",
"    In referrals in which the consultant is requested to \"clear\" the patient or in referrals in which no specific question is asked, the consultant can presume that the request is to provide a more global preoperative evaluation as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is wrong and how bad is as it? &mdash; Assess overall risk, including risk of cardiac and pulmonary morbidity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"       \"Evaluation of preoperative pulmonary risk\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is the patient in his or her optimal medical condition for the procedure or should further treatment or tests be done? &mdash; Decide whether further interventions are indicated to decrease the stated risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      What can we do to prevent known complications? &mdash; Make recommendations about prophylaxis for venous thromboembolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/23\">",
"       23",
"      </a>",
"      ], endocarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/24\">",
"       24",
"      </a>",
"      ], and, possibly surgical wound infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/25\">",
"       25",
"      </a>",
"      ]. Many surgeons view surgical wound infection prophylaxis as their domain, but consultants who notice that surgical wound prophylaxis is not being given should consider providing recommendations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      What should we do concerning perioperative medications? &mdash; Make recommendations about perioperative management of the patient's usual outpatient medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link\">",
"       \"Perioperative medication management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Performing the consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experienced consultant should be able to identify the pertinent medical problems, integrate this information with the physiologic stresses of anesthesia and surgery (see above), anticipate potential perioperative problems, assess a patient's risk and need for further interventions, and communicate effectively with the surgeon and anesthesiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Responsibilities of the consultant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six of the AMA's ethical principles of consultation address the responsibilities and role of the consultant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One physician should be in charge of the patient's care.",
"     </li>",
"     <li>",
"      The attending physician has overall responsibility for the patient's treatment.",
"     </li>",
"     <li>",
"      The consultant should not assume primary care of the patient without consent of the referring physician.",
"     </li>",
"     <li>",
"      The consultation should be done punctually.",
"     </li>",
"     <li>",
"      Discussions during the consultation should be with the referring physician and only with the patient by prior consent of the referring physician.",
"     </li>",
"     <li>",
"      Conflicts of opinion should be resolved by a second consultation or withdrawal of the consultant; however, the consultant has the right to give his or her opinion to the patient in the presence of the referring physician.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Avoiding anesthetic recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a consultant, the physician should restrict advice to his or her area of expertise. For internists, this usually includes general internal medicine or cardiology and various aspects of perioperative medicine, depending upon experience. Only the anesthesiologist should make recommendations as to the type of anesthesia. The internist may be one of several consultants, and he or she should coordinate and integrate the recommendations of these subspecialty consultants, but should not take control away from the referring physician. On the other hand, the consultant's understanding of anesthetic techniques and physiology can help ensure a safe anesthetic experience and adequate postoperative analgesia with fewer complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Avoiding issues not related to the procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the general internist's usual initial visit, which includes performing a comprehensive history and physical examination with multiple risk factor assessment and preventive health maintenance, the perioperative consultation should focus only upon the issues relevant to the current surgery. These immediate concerns must be evaluated in terms of their severity, the planned surgical procedure, the patient's perioperative risk, and the need for further testing or intervention. Any other issues can be addressed after surgery or during a subsequent outpatient visit, and the consultant should make arrangements for appropriate follow-up to assure continuity of care after discharge.",
"   </p>",
"   <p>",
"    Most internists agree with this approach. However, some believe that this encounter may be the only time a patient has seen a physician and therefore want to do as much screening and education as possible. The disadvantage of this latter approach is that the referring physician can become bogged down with a long list of recommendations that may be ignored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Discussion with the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients are interested in knowing the consultant's opinion at the end of the consultation visit. Unless the consultant is the patient's primary care physician, he or she should not express an opinion as to whether surgery should proceed. The final decision is best made by the surgeon in conjunction with the patient.",
"   </p>",
"   <p>",
"    Consultants differ in whether any estimate of the risk of perioperative medical complications should be communicated to the patient. Some choose to provide an estimate while others prefer to defer that discussion to the surgeon or anesthesiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLIANCE WITH CONSULTANT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that have examined the compliance of referring physicians with the recommendations of consultants have found that compliance ranges from 54 to 95 percent depending upon the setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/28-32\">",
"     28-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following factors or advice have been shown to improve compliance with the medical consultant's recommendations (",
"    <a class=\"graphic graphic_table graphicRef63273 \" href=\"mobipreview.htm?10/47/11003\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As discussed previously, the central reason for the consultation request needs to be clearly stated, understood, and addressed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16,30,32\">",
"       16,30,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The consultant should respond in a timely fashion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/33\">",
"       33",
"      </a>",
"      ]. Urgent consultations should be seen promptly, and elective consultations should be answered so as not to cause a delay in surgery. In general, all consultations should be done within 24 hours, and preferably the same day as requested. Any anticipated delays should be communicated immediately to the referring physician.",
"     </li>",
"     <li>",
"      The consultant's recommendations should be definitive, prioritized, and precise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16,18,28,33,34\">",
"       16,18,28,33,34",
"      </a>",
"      ]. The number of recommendations should be limited when possible, preferably to five or fewer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/30,31,35\">",
"       30,31,35",
"      </a>",
"      ]. Recommendations identified as \"crucial\" or \"critical\" are more likely to be followed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/29-31,35\">",
"       29-31,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The consultant should use definitive language [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16,18,28,33,34\">",
"       16,18,28,33,34",
"      </a>",
"      ] and specify relevant recommendations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/18,28,34\">",
"       18,28,34",
"      </a>",
"      ]. Recommendations for medications should specify the drug name, dose, frequency, route of administration, and duration of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/18,33,35\">",
"       18,33,35",
"      </a>",
"      ]. Alternatives to a recommended therapy should be mentioned if available.",
"     </li>",
"     <li>",
"      Therapeutic recommendations are more likely to be followed than diagnostic recommendations, but recommendations to start therapy may be less likely to be followed than those to continue or discontinue therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/30,33\">",
"       30,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Direct verbal communication with the requesting physician is preferable to communicating via the chart [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16,18,31\">",
"       16,18,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frequent follow-up visits documented with progress notes are key in improving compliance with the consultant's recommendations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/33,35\">",
"       33,35",
"      </a>",
"      ]. How often a consultant needs to see a patient will depend upon the patient's medical problems and type of surgery. When the consultant no longer needs to follow the patient, he should write a note indicating that he is signing off the case. He should also make arrangements to assure continuity of care for medical problems after the patient is discharged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principles were illustrated in a report that analyzed 202 general medical consultations to assess the extent of compliance with the consultant's initial recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/30\">",
"     30",
"    </a>",
"    ]. Multivariate analysis found that the clinical severity of the patients' illnesses and the type and number of recommendations were all predictors of compliance. There was a significant increase in compliance in severely ill patients; with each severity level, compliance was higher when five or fewer recommendations were made. Compliance decreased from 96 percent in severely ill patients with small consultation lists to 79 percent in those with large lists. Compliance was greatest with recommendations involving medications, and least with those requiring direct physician and nursing action, suggesting that the consultant must carefully follow-up the latter recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comanagement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many settings, the consultant steps beyond the usual role of consultant and writes orders in the medical record; this practice is known as comanagement. The prevalence of comanagement is unknown but, in the authors' opinion, quite high, especially with the increasing numbers of hospitalists. Comanagement is seen most often in orthopedic surgery patients.",
"   </p>",
"   <p>",
"    Permission of the surgeon or surgical team is required before a consultant writes orders. Some surgeons work predominantly with a few medical consultants in whom the expectation is that orders will be written. The advantage to the consultant in writing orders is that it guarantees compliance. A potential disadvantage of this practice is duplicate or conflicting orders if the consultant or surgeon is not knowledgeable about all orders in the chart. In addition, if a consultant writes orders in a chart, and a malpractice suit is brought, the culpability of any consultants may be higher than if they provided only recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of hospitalists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalists are assuming a larger role in the United States in preoperative medical consultation and perioperative management. Hospitalist medical consultants often undertake additional responsibilities, including serving as co-managers. They are concerned with processes of care, patient safety measures, and adherence to practice guidelines. Additionally, they function as liaisons between the surgical care team and the patient's primary care clinician, coordinate hospital care, and facilitate discharge planning and follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/36\">",
"     36",
"    </a>",
"    ] . The hospitalist model of care for orthopedic surgery patients has resulted in a decreased time to consultation and time to surgery, and a trend toward decreased length of stay and lower hospital costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41735/abstract/28,37-39\">",
"     28,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/52/30530?source=see_link\">",
"       \"Patient information: Questions to ask if you are having a procedure or surgery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No study has shown a decrease in perioperative morbidity associated with medical consultation. Nevertheless, the practice of medical consultation is widespread and, assuming consultants make evidence-based recommendations that improve surgical outcomes, it is reasonable to infer that consultation will improve the care of the surgical patient if consultative recommendations are implemented. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effect on surgical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of the consultant should be defined through communication with the referring physician. A requesting physician should state clearly the questions to be answered by the consultant. Advice should be specific to the questions asked. Given the high frequency of misunderstanding between consultants and referring physicians, direct communication is important and likely will prevent misinterpretation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Reasons for consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A commonly stated purpose of a preoperative consultation request is to \"clear\" a patient for surgery. This statement may incorrectly imply that the procedure carries no risk for the particular patient, when all patients are potentially at some risk when they undergo anesthesia and surgery. Thus, a consultant should avoid use of the phrase \"cleared for surgery.\" (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Implications of clearing a patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The experienced consultant should be able to identify the pertinent medical problems, anticipate potential perioperative problems, avoid addressing issues outside of the consultant's area of expertise or issues unrelated to the procedure, assess a patient's risk and need for further interventions, and communicate effectively with the surgeon and anesthesiologist. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Performing the consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compliance with consultant recommendations improves with increasing severity of the patient illness and when fewer recommendations are made by the consultant. The number of recommendations should be limited when possible, preferably to five or fewer. The consultant should respond in a timely fashion (&lt;24 hours) and make precise, relevant recommendations. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Compliance with consultant recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the consultant no longer needs to follow the patient, a note should be written indicating that he or she is signing off the case. Arrangements should be made to assure continuity of care for medical problems after the patient is discharged. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Compliance with consultant recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/1\">",
"      Devor M, Renvall M, Ramsdell J. Practice patterns and the adequacy of residency training in consultation medicine. J Gen Intern Med 1993; 8:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/2\">",
"      McKean SC, Budnitz TL, Dressler DD, et al. How to use the core competencies in hospital medicine: a framework for curriculum development. J Hosp Med 2006; 1 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/3\">",
"      Levinson W. Preoperative evaluations by an internist--are they worthwhile? West J Med 1984; 141:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/4\">",
"      Devereaux PJ, Ghali WA, Gibson NE, et al. Physicians' recommendations for patients who undergo noncardiac surgery. Clin Invest Med 2000; 23:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/5\">",
"      Clelland C, Worland RL, Jessup DE, East D. Preoperative medical evaluation in patients having joint replacement surgery: added benefits. South Med J 1996; 89:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/6\">",
"      Macpherson DS, Lofgren RP. Outpatient internal medicine preoperative evaluation: a randomized clinical trial. Med Care 1994; 32:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/7\">",
"      Mollema R, Berger P, Girbes AR. The value of peri-operative consultation on a general surgical ward by the internist. Neth J Med 2000; 56:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/8\">",
"      Auerbach AD, Wachter RM, Cheng HQ, et al. Comanagement of surgical patients between neurosurgeons and hospitalists. Arch Intern Med 2010; 170:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/9\">",
"      Macpherson DS, Parenti C, Nee J, et al. An internist joins the surgery service: does comanagement make a difference? J Gen Intern Med 1994; 9:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/10\">",
"      Phy MP, Vanness DJ, Melton LJ 3rd, et al. Effects of a hospitalist model on elderly patients with hip fracture. Arch Intern Med 2005; 165:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/11\">",
"      Auerbach AD, Rasic MA, Sehgal N, et al. Opportunity missed: medical consultation, resource use, and quality of care of patients undergoing major surgery. Arch Intern Med 2007; 167:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/12\">",
"      Wijeysundera DN, Austin PC, Beattie WS, et al. Outcomes and processes of care related to preoperative medical consultation. Arch Intern Med 2010; 170:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/13\">",
"      Goldman L, Lee T, Rudd P. Ten commandments for effective consultations. Arch Intern Med 1983; 143:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/14\">",
"      Salerno SM, Hurst FP, Halvorson S, Mercado DL. Principles of effective consultation: an update for the 21st-century consultant. Arch Intern Med 2007; 167:271.",
"     </a>",
"    </li>",
"    <li>",
"     Opinions and reports of the judicial council. Chicago: American Medical Association, 1960.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/16\">",
"      Lee T, Pappius EM, Goldman L. Impact of inter-physician communication on the effectiveness of medical consultations. Am J Med 1983; 74:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/17\">",
"      Kleinman B, Czinn E, Shah K, et al. The value to the anesthesia-surgical care team of the preoperative cardiac consultation. J Cardiothorac Anesth 1989; 3:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/18\">",
"      Rudd P, Siegler M, Byyny RL. Perioperative diabetic consultation: a plead for improved training. J Med Educ 1978; 53:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/19\">",
"      Katz RI, Cimino L, Vitkun SA. Preoperative medical consultations: impact on perioperative management and surgical outcome. Can J Anaesth 2005; 52:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/20\">",
"      Choi JJ. An anesthesiologist's philosophy on 'medical clearance' for surgical patients. Arch Intern Med 1987; 147:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/21\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/22\">",
"      Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. American College of Physicians. Ann Intern Med 1997; 127:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/23\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/25\">",
"      Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2006; 52:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/26\">",
"      Cygan R, Waitzkin H. Stopping and restarting medications in the perioperative period. J Gen Intern Med 1987; 2:270.",
"     </a>",
"    </li>",
"    <li>",
"     Perioperative Medicine - Just the Facts, Cohn SL, Smetana GW, Weed HG (Eds), McGraw Hill, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/28\">",
"      Klein LE, Levine DM, Moore RD, Kirby SM. The preoperative consultation. Response to internists' recommendations. Arch Intern Med 1983; 143:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/29\">",
"      Ballard WP, Gold JP, Charlson ME. Compliance with the recommendations of medical consultants. J Gen Intern Med 1986; 1:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/30\">",
"      Sears CL, Charlson ME. The effectiveness of a consultation. Compliance with initial recommendations. Am J Med 1983; 74:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/31\">",
"      Pupa LE Jr, Coventry JA, Hanley JF, Carpenter JL. Factors affecting compliance for general medicine consultations to non-internists. Am J Med 1986; 81:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/32\">",
"      Ferguson RP, Rubinstien E. Preoperative medical consultations in a community hospital. J Gen Intern Med 1987; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/33\">",
"      Horwitz RI, Henes CG, Horwitz SM. Developing strategies for improving the diagnostic and management efficacy of medical consultations. J Chronic Dis 1983; 36:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/34\">",
"      Klein LE, Moore RD, Levine DM, Kirby S. Effectiveness of medical consultation. J Med Educ 1983; 58:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/35\">",
"      Mackenzie TB, Popkin MK, Callies AL, et al. The effectiveness of cardiology consultation. Concordance with diagnostic and drug recommendations. Chest 1981; 79:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/36\">",
"      Adesanya AO, Joshi GP. Hospitalists and anesthesiologists as perioperative physicians: Are their roles complementary? Proc (Bayl Univ Med Cent) 2007; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/37\">",
"      Batsis JA, Phy MP, Melton LJ 3rd, et al. Effects of a hospitalist care model on mortality of elderly patients with hip fractures. J Hosp Med 2007; 2:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/38\">",
"      Roy A, Heckman MG, Roy V. Associations between the hospitalist model of care and quality-of-care-related outcomes in patients undergoing hip fracture surgery. Mayo Clin Proc 2006; 81:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41735/abstract/39\">",
"      Huddleston JM, Long KH, Naessens JM, et al. Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial. Ann Intern Med 2004; 141:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4815 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41735=[""].join("\n");
var outline_f40_48_41735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECT ON SURGICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Needs of the requesting physician",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Reasons for consultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Implications of clearing a patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Performing the consultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Responsibilities of the consultant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Avoiding anesthetic recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Avoiding issues not related to the procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Discussion with the patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLIANCE WITH CONSULTANT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comanagement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of hospitalists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/47/11003\" title=\"table 1\">",
"      Compliance with medical consult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/52/30530?source=related_link\">",
"      Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41736="Chemoprevention strategies in prostate cancer";
var content_f40_48_41736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemoprevention strategies in prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     E David Crawford, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41736/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/48/41736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the incidence of prostate cancer dramatically rose in the early 1990s in conjunction with the increasing utilization of prostate specific antigen (PSA) screening. After an initial peak, incidence rates fell, but they have persisted at a rate nearly twice that recorded in the pre-PSA era, suggesting that many cases are clinically indolent and would never have become clinically apparent. Despite the increase in diagnosis of early stage prostate cancer, the impact of earlier treatment on survival remains to be proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H31#H31\">",
"     \"Screening for prostate cancer\", section on 'Overdiagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high incidence of prostate cancer, its associated morbidity and mortality, the complications associated with its treatment, and a partial understanding of its biologic basis have led to a focus on chemoprevention strategies. The most extensive data come from the use of 5-alpha reductase (5-AR) inhibitors; other classes of agents are also being explored.",
"   </p>",
"   <p>",
"    The rationale for chemoprevention, the results with the 5-AR inhibitors, and data with other approaches are presented here. Screening for prostate cancer, an alternative approach that focuses on early detection to decrease morbidity and mortality, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three factors have contributed to the rationale for prostate cancer chemoprevention in men: the long latency period between the initial evidence of prostate cancer and the development of overt or fatal disease, the androgen dependency of these tumors, and the availability of intermediate endpoints for use in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Long latency period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The marked discrepancy between the autopsy prevalence of occult prostate cancer and the incidence of clinically manifest disease indicate that there is a long latency phase and significant heterogeneity in the rate of progression of early neoplastic lesions. Progression to invasive cancer in men with high-grade prostatic intraepithelial neoplasia (HG_PIN) may take 10 years or more.",
"   </p>",
"   <p>",
"    As a result, chemoprevention strategies that do not reverse the premalignant condition but merely delay its progression to invasive cancer may be sufficient to improve survival or avoid the complications of the disease or its treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Androgen dependency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct or indirect androgenic influences are important in the malignant transformation of prostatic tissue. Men with 5-alpha reductase (5-AR) deficiency (the enzyme that converts testosterone to dihydrotestosterone [DHT], the most active androgen in the prostate) do not develop prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precursor lesion, high-grade prostatic intraepithelial neoplasia (HG-PIN), is also hormonally dependent. The atrophy and apoptotic changes that occur with androgen deprivation in normal and hyperplastic prostatic epithelium and in invasive cancers are also observed in PIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that interference with normal androgen balance may affect prostate cancer incidence. Medical therapies directed at hormonal manipulation include estrogens, antiandrogens, gonadotropin releasing hormone (GnRH) agonists, and 5-AR inhibitors. Most of these therapies are not candidates for use as chemopreventive agents because of potential side effects. The use of 5-AR inhibitors or antiandrogens that block the androgen receptor may be associated with fewer side effects because serum testosterone levels remain unaltered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical trials biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of a chemopreventive agent may be facilitated by the availability of biomarkers that may predict the subsequent development of prostate cancer or can be used to define its progression and thus serve as intermediate endpoints for clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostatic intraepithelial neoplasia &mdash; Prostatic intraepithelial neoplasia (PIN) represents a spectrum of dysplastic changes that are limited to prostatic acini and do not invade the basement membrane. Current classification schemes describe low-grade and high-grade PIN. Only HG-PIN is thought to be associated with an increased prostate cancer risk. The pathologic features of PIN and the relationship to cancer are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26937?source=see_link&amp;anchor=H2#H2\">",
"       \"Precancerous lesions of the prostate: Pathology and clinical implications\", section on 'Prostatic intraepithelial neoplasia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      HG-PIN is an attractive biomarker for use as an intermediate endpoint in prostate cancer chemoprevention trials because it precedes the development of invasive prostate cancer and is accessible for serial study, both in repeat prostate biopsies and in radical prostatectomy specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. In autopsy series, HG-PIN is identifiable decades before clinical progression of prostate cancer is likely to become manifest and is even seen in specimens from men in their thirties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PSA &mdash; Changes in serum PSA concentration and its association with prostate cancer suggest that serum PSA may be a useful biomarker and that defined changes could act as intermediate end points in the setting of chemoprevention trials. However, serum PSA is also secreted by normal prostate tissue and as an androgen regulated gene, levels are incompletely correlated with tumor burden. Techniques to increase its sensitivity and specificity are thus desirable, especially in the range of 4 to 10",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      These issues are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"       \"Measurement of prostate specific antigen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     5-ALPHA REDUCTASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of 5-AR blocks production of the most potent androgen involved in prostate cancer pathogenesis. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Androgen dependency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 5-AR inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    are used primarily for the treatment of benign prostatic hyperplasia (BPH). They reduce serum PSA levels by an average of 50 percent, which can affect the use of serum PSA for prostate cancer detection in men treated with these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link&amp;anchor=H10#H10\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on '5-alpha-reductase inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for prostate cancer\", section on 'Measuring PSA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Finasteride",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    is an inhibitor of the type 2 5-AR and has been demonstrated to be safe and well tolerated in large long-term trials for the treatment of BPH. Blocking the conversion of testosterone to DHT results in a significant reduction of DHT with normal or increased serum testosterone levels, an effect that may limit side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prostate Cancer Prevention Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    was tested as a chemopreventive agent in the Prostate Cancer Prevention Trial (PCPT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/11\">",
"     11",
"    </a>",
"    ]. The 18,882 men enrolled in this trial were considered at elevated risk of prostate cancer based upon age &ge;55 years, African-American ethnicity, or having a first-degree relative with prostate cancer. All had a normal digital rectal examination (DRE) and a serum PSA &le;3",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Subjects were randomly assigned to finasteride (5 mg per day) or placebo.",
"   </p>",
"   <p>",
"    Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (which decreases the serum PSA by approximately 50 percent) was &ge;4",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    or if the DRE became abnormal. In addition, all men were offered a prostate biopsy at the end of study (seven years).",
"   </p>",
"   <p>",
"    The PCPT was closed early because the primary study endpoint (ie, a decrease in the prevalence of biopsy-proven prostate cancer in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    population compared to placebo) was met. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a 25 percent decrease in the incidence of prostate cancer in men assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      (803 of 4368 [18.4 percent] versus 1147 of 4692 [24.4 percent] with placebo). The magnitude of the risk reduction did not differ according to PSA level, age,",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      or family history of prostate cancer.",
"     </li>",
"     <li>",
"      Despite the overall decrease in cases of prostate cancer among those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      , both the absolute number and proportion of more aggressive prostate cancers (ie, Gleason score &ge;7) were significantly higher in the finasteride group (280 of 757 [37 percent] versus 237 of the 1068 [22 percent] in the placebo group). However, 98 percent of tumors were T1 or T2 in both groups, and only five men in each group died of prostate cancer.",
"     </li>",
"     <li>",
"      Treatment was well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       Finasteride",
"      </a>",
"      increased sexual dysfunction only slightly by six months after randomization compared to placebo, and its impact diminished over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/13\">",
"       13",
"      </a>",
"      ]. Urinary symptoms were less common in the finasteride group (frequency or urgency, 12.9 versus 15.6 percent with placebo, urinary retention, 4.2 versus 6.3 percent, need for transurethral resection of the prostate, 1.0 versus 1.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk of high-grade prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the reduction in the total number of prostate cancers in the PCPT, the observed increase in numbers of patients with high-grade cancers has dampened enthusiasm for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    as a chemopreventive agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of subsequent analyses have suggested that the observed increase in high-grade lesions does not represent a true alteration in the biology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. As an example, an observational reanalysis of the PCPT results supported a diagnostic bias due to the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    on prostate size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients treated with finasteride had a significantly smaller prostate volume (median 25.1 cm3 versus 33.5 cm3 with placebo). This reduction in prostate volume appeared to result in a disproportionate sampling of the gland and tumor during random needle biopsy, thereby increasing identification of areas of high-grade tumor. When the effect of prostate size was incorporated into the analysis, the increased risk of high-grade prostate cancer with finasteride compared to placebo disappeared (odds ratio [OR] 1.03, 95% CI 0.84 to 1.26 versus OR 1.27 95% CI 1.05 to 1.54 when the size of the prostate gland was not considered).",
"   </p>",
"   <p>",
"    Although an increase in biologic aggressiveness cannot be definitively ruled out, these results provide some reassurance that chemoprevention with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    does not result in a clinically relevant increase in the number of high-grade prostate cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/15\">",
"     15",
"    </a>",
"    ]. However, there are no data that indicate that finasteride chemoprevention decreases overall mortality from prostate cancer, and this was not the primary end point of the PCPT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dutasteride",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     Dutasteride",
"    </a>",
"    inhibits both type 1 and type 2 5-alpha-reductase (AR). Dutasteride suppresses DHT by greater than 90 percent, compared to 70 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In a preliminary report of a small randomized placebo-controlled study involving 43 men with BPH, dutasteride reduced intraprostatic DHT levels by 94 percent; however this was associated with an increase in intraprostatic testosterone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The short-term administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    causes significant alterations in both benign and neoplastic prostate tissue, consistent with a chemopreventive or chemoactive role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/23\">",
"     23",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , dutasteride reduces PSA levels by a little more than one-half [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    on the incidence of prostate cancer were evaluated in the double-blind REDUCE trial, in which 8336 men were randomly assigned to dutasteride (0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four years) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/24\">",
"     24",
"    </a>",
"    ]. All men were considered at increased risk for prostate cancer, based upon age, serum PSA level, and all had a single negative prostate biopsy within six months prior to protocol entry. Men 50 to less than 60 years of age had a baseline serum PSA of 2.5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    while those 60 to 75 years of age had a PSA 3 to 10",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    The protocol called for repeat 10-core biopsies at two and four years after treatment initiation.",
"   </p>",
"   <p>",
"    Key findings from this trial included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of prostate cancer was significantly reduced in men assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      compared to placebo (25.1 versus 19.9 percent, relative risk reduction 23 percent). This risk reduction was observed in all major prespecified risk groups.",
"     </li>",
"     <li>",
"      Analysis of Gleason scores in those diagnosed with prostate cancer found that the decrease in incidence was primarily in those with Gleason scores of 5 or 6, which constituted 70 percent of all cases diagnosed. There was no statistically significant difference in those with Gleason scores of 7 to 10. In those with Gleason scores 8 to 10, there was no difference at two years (17 and 18 cases with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      and placebo, respectively). However, at four years there was a statistically significant increase in those treated with dutasteride compared to placebo (12 versus 1 case, respectively).",
"     </li>",
"     <li>",
"      The side effects associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      were consistent with those seen in other trials with this agent and included erectile dysfunction, decreased libido, and gynecomastia (9.0 versus 5.7, 3.3 versus 1.6, and 1.9 versus 1.0 percent, respectively, compared to placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Guidelines and regulatory status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from an expert panel of the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) identified key issues that physicians and men should consider in deciding whether or not to use a 5-AR inhibitor for prostate cancer chemoprevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      5-AR inhibitors decrease, but do not eliminate, the risk of prostate cancer.",
"     </li>",
"     <li>",
"      An elevated rate of high-grade prostate cancers has been observed in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/11\">",
"       11",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/24\">",
"       24",
"      </a>",
"      ], although the significance of this observation remains unclear.",
"     </li>",
"     <li>",
"      There is no information about whether these agents decrease the risk of death from prostate cancer or affect overall survival. There is also no information about the effects of their use beyond seven years.",
"     </li>",
"     <li>",
"      Side effects of these agents include gynecomastia, decreased libido, erectile dysfunction, and decreased ejaculate volume. At the same time, these agents may decrease urinary tract symptoms due to benign prostatic hyperplasia (BPH).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the United States Food and Drug Administration (FDA) has not approved the use of these agents for prostate cancer prevention due to potential concerns about risks and long-term safety. An advisory committee to the FDA concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    do not have a favorable risk-benefit profile for the chemoprevention of prostate cancer in healthy men, with an estimation that one additional high grade cancer would occur for every three to four lower grade cancers that would be prevented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other agents are being studied to prevent prostate cancer. All of these remain experimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12994978\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have variably suggested that men treated with statins have a decreased risk of prostate cancer, particularly high-grade disease. The results of those studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H33#H33\">",
"     \"Risk factors for prostate cancer\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vitamins and micronutrients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data on vitamins and dietary supplements for chemoprevention is extensive and difficult to interpret. Currently available data have not established a role for any of these agents in the prevention of prostate cancer.",
"   </p>",
"   <p>",
"    The most extensively studied agents are vitamin E (alpha tocopherol) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have shown that vitamin E has potent inhibitory activity on cell proliferation in various cancer cell lines, particularly prostate cancer, and high molecular weight DNA analysis reveals fragmentation consistent with apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/28\">",
"     28",
"    </a>",
"    ]. Mechanistically, vitamin E may inhibit NF-kappaB-dependent genes in prostate cancer cells, whose dysregulation is implicated in the process of malignant transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from observational studies yielded conflicting results. Several case-control studies suggested that vitamin E supplementation decreases the risk of prostate cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], while two of three large cohort studies did not demonstrate a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials, the alpha-tocopherol",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    (ATBC) intervention trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/36-38\">",
"     36-38",
"    </a>",
"    ] and the Heart Outcomes Prevention Evaluation-The Ongoing Outcomes (HOPE-TOO) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/39\">",
"     39",
"    </a>",
"    ], provided conflicting evidence regarding the incidence of prostate cancer as a secondary outcome. Two randomized trials specifically designed to study the impact of vitamin E on prostate cancer failed to provide any evidence supporting a chemopreventive role in men at risk for prostate cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SELECT trial was designed to study the role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      and vitamin E as agents to decrease the incidence of prostate cancer. In this trial, 35,533 men were randomly assigned to selenium (200",
"      <span class=\"nowrap\">",
"       microg/day),",
"      </span>",
"      vitamin E (400 international",
"      <span class=\"nowrap\">",
"       units/day),",
"      </span>",
"      both, or neither, with appropriate placebos [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/40\">",
"       40",
"      </a>",
"      ]. This trial was stopped in October 2008, after an independent data safety monitoring committee found no evidence of a decrease in the incidence of prostate cancer. Dietary supplementation with vitamin E significantly increased the incidence of prostate cancer, and there were nonsignificant increases with selenium and the combination of vitamin E plus selenium compared with placebo (hazard ratios for developing prostate cancer 1.17, 1.09, and 1.05, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Physicians' Health Study II (PHS II) was a double-blind, placebo-controlled trial in which 14,641 male physicians ages 55 years and older were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      , vitamin E, ascorbic acid,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a multivitamin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/43\">",
"       43",
"      </a>",
"      ]. One of the primary end points of this study was the prevention of prostate cancer. The incidence of prostate cancer was not significantly reduced with any of the agents, including vitamin E (hazard ratio 0.97, 95% CI 0.85-1.09) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current evidence does not support a role for vitamin E supplementation in the prevention or treatment of cancers, cardiovascular disease, dementia, and infection. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link&amp;anchor=H26#H26\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Vitamin E'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Selenium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple mechanisms have been proposed by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    may have a chemopreventive effect, including inhibition of cell invasion, DNA repair, stimulation of transforming growth factor-beta signaling, and inhibition of androgen receptor signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/45\">",
"     45",
"    </a>",
"    ]. Selenium, taken as an oral supplement, preferentially accumulates in the human prostate gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/46\">",
"     46",
"    </a>",
"    ]. Data from preliminary studies was conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    supplementation was directly evaluated the SELECT trial that included 35,533 men at risk for prostate cancer. There was no evidence of any chemopreventive effect from supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/42\">",
"     42",
"    </a>",
"    ]. The incidence of prostate cancer was nonsignificantly increased with selenium alone or in combination with vitamin E (hazard ratios 1.09 and 1.05, respectively). The results of this trial are discussed above. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Vitamin E'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Vitamin D analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A link between vitamin D levels and prostate cancer risk has been suggested, mainly based upon the association of vitamin D deficiency and epidemiologic risk factors such as age, African-American race, and geographic area of residence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/49-56\">",
"     49-56",
"    </a>",
"    ]. Preclinical studies support an antiproliferative, antimetastatic, and differentiating effect of vitamin D and its analogues in prostate cancer, providing a rationale for the consideration of these compounds as potential chemopreventive agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoids are metabolites and analogs of vitamin A, which are required for the proper differentiation of various epithelial tissues, and they play a regulatory role in the activation of cytokines and the extracellular matrix. Chemoprevention trials are ongoing with retinoids in lung cancer, breast cancer, and head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19017?source=see_link\">",
"     \"Chemoprevention in oral dysplasia and head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fenretinide, a synthetic retinoid, has been evaluated in men with prostate cancer in preliminary studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. However, these trials have not yielded evidence of activity, and this class of agents is not under active investigation for chemoprevention against prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Toremifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30181?source=see_link\">",
"     Toremifene",
"    </a>",
"    is a selective estrogen receptor modulator that decreased the incidence of prostate cancer in an animal model.",
"   </p>",
"   <p>",
"    Based upon results from a phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/60\">",
"     60",
"    </a>",
"    ], a phase III trial was conducted in 1590 men with high-grade prostatic intraepithelial neoplasia (HG-PIN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/61\">",
"     61",
"    </a>",
"    ]. Study participants were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30181?source=see_link\">",
"     toremifene",
"    </a>",
"    or placebo for three years, and followed with prostate biopsies annually throughout the study. There was no statistically significant decrease in the prostate cancer free survival estimate at three years (59.5 versus 54.9 percent, p = 0.39, for toremifene and placebo, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some epidemiologic evidence that regular use of NSAIDs, which inhibit cyclooxygenase-2 (COX-2), may be associated with a lower risk of prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H32#H32\">",
"     \"Risk factors for prostate cancer\", section on 'Use of NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated prostaglandin levels and upregulation of COX-2, a key enzyme in the conversion of arachidonic acid to prostaglandins, are found in prostate cancer cell lines, and apoptosis follows the withdrawal of arachidonic acid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its metabolites. Experimental evidence suggests differential expression of COX-2 in normal prostatic stroma, with upregulation in premalignant as well as malignant prostate epithelium, and regression of PIN has been seen in murine models after administration of NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data provide a rationale for considering the use of NSAIDs as chemopreventive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/63\">",
"     63",
"    </a>",
"    ]. However, a planned prostate cancer prevention trial with rofecoxib was canceled when the drug was withdrawn from the market because of unexpected cardiovascular toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of dietary factors have been analyzed for their association with the risk of prostate cancer. Although information from these studies may be useful in defining new approaches to chemoprevention, none of these have an established role in prostate cancer chemoprevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for prostate cancer\", section on 'Diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phytoestrogens (flavones, isoflavones, lignans) are naturally occurring plant compounds that have estrogen-like activity. Genistein and daidzein, the predominant isoflavones in human nutrition, are derived mainly from soybeans and other legumes.",
"   </p>",
"   <p>",
"    Phytoestrogens may reduce prostate cancer risk either via their inherent estrogenic properties (which favorably alters the hormonal milieu) or by inhibition of 5-alpha reductase (5-AR), which decreases concentrations of the more prostate-active androgen dihydrotestosterone (DHT). The higher intake of soy products among Asian men has been hypothesized to be one reason for the lower incidence of prostate cancer among these men.",
"   </p>",
"   <p>",
"    The most provocative data linking soy or phytoestrogen exposure to a reduced prostate cancer risk come from animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. In humans, most of the case-control studies have shown a modest protective benefit of soy on prostate cancer risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk factors for prostate cancer\", section on 'Soy intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one randomized trial, 310 men with high-grade prostatic intraepithelial neoplasia were randomly assigned to a combination of vitamin E, soy, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , or to placebo. There was no evidence that the combination prevented progression to prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41736/abstract/67\">",
"     67",
"    </a>",
"    ]. Several other randomized, placebo-controlled clinical trials evaluating soy protein in men with treated prostate cancer who are at high risk for recurrence are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high incidence of prostate cancer, its associated morbidity and mortality, and its hormone dependency all have made prostate cancer an important target for chemopreventive strategies. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rationale'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In randomized trials, 5-alpha-reductase (5-AR) inhibitors have been shown to significantly decrease the incidence of prostate cancer. However, no trials have demonstrated an impact of prostate cancer mortality, and the possibility that these agents increase the incidence of high-grade lesions cannot be excluded. (See",
"    <a class=\"local\" href=\"#H6\">",
"     '5-Alpha reductase inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential side effects (gynecomastia, decreased libido, erectile dysfunction), benefits (decreased symptoms from benign prostatic hyperplasia), and areas of uncertainty (impact on survival, long-term side effects) should be explained to men considering chemopreventive therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men who consider preventing cancer more important than the side effects and uncertainties associated with chemoprevention, we suggest therapy with a 5-AR inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       '5-Alpha reductase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those more concerned about the side effects and uncertainties of a 5-AR inhibitor, we suggest not using chemopreventive therapy with a 5-AR inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       '5-Alpha reductase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data that support the use of vitamin E,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , or other agents for routine use, and such agents remain experimental. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Other agents'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/2\">",
"      Gaudin PB, Sesterhenn IA, Wojno KJ, et al. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997; 49:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/3\">",
"      Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/4\">",
"      Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/5\">",
"      Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/6\">",
"      Einspahr JG, Alberts DS, Gapstur SM, et al. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev 1997; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/7\">",
"      Sakr WA. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention. Eur Urol 1999; 35:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/8\">",
"      Trump DL, Waldstreicher JA, Kolvenbag G, et al. Androgen antagonists: Potential role in prostate cancer prevention. Urology 2001; 57:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/9\">",
"      Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/10\">",
"      Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006; 175:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/11\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/12\">",
"      Moinpour CM, Darke AK, Donaldson GW, et al. Health-related quality-of-life findings for the prostate cancer prevention trial. J Natl Cancer Inst 2012; 104:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/13\">",
"      Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/14\">",
"      Andriole GL, Humphrey PA, Serfling RJ, Grubb RL. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst 2007; 99:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/15\">",
"      Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/16\">",
"      Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/17\">",
"      Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) 2008; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/18\">",
"      Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008; 1:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/19\">",
"      Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) 2008; 1:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/20\">",
"      Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/21\">",
"      McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/22\">",
"      Wurzel R, Ray P, Major-Walker KY, Shannon JB. Inhibition of type I and type II 5alpha-reductase with dutasteride (0.5 mg) significantly reduces intraprostatic dihydrotestosterone in BPH patients (abstract). J Urol 2006; 175 (4Suppl):527s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/23\">",
"      Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005; 65:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/24\">",
"      Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/25\">",
"      Kramer BS, Hagerty KL, Justman S, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009; 27:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/26\">",
"      Kramer BS, Hagerty KL, Justman S, et al. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009; 181:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/27\">",
"      Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5&alpha;-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/28\">",
"      Sigounas G, Anagnostou A, Steiner M. dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 1997; 28:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/29\">",
"      Crispen PL, Golovine K, Markov P, et al. Inhibition of NF-kB in Prostate Cancer Cells by Vitamin E Succinate (VES) Decreases Metastatic Potential by Altering Expression of Pro-metastatic Molecules and Decreasing Cell Invasiveness and Adhesion (abstract). J Urol 2006; 175(suppl 4):261s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/30\">",
"      Wilkinson S, Chodak GW. Critical review of complementary therapies for prostate cancer. J Clin Oncol 2003; 21:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/31\">",
"      Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/32\">",
"      Kristal AR, Stanford JL, Cohen JH, et al. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/33\">",
"      Chan JM, Stampfer MJ, Ma J, et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/34\">",
"      Kirsh VA, Hayes RB, Mayne ST, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/35\">",
"      Rodriguez C, Jacobs EJ, Mondul AM, et al. Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2004; 13:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/36\">",
"      The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/37\">",
"      Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/38\">",
"      Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003; 290:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/39\">",
"      Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/40\">",
"      Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/41\">",
"      Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/42\">",
"      Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/43\">",
"      Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/44\">",
"      Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/45\">",
"      Dong Y, Zhang H, Hawthorn L, et al. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003; 63:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/46\">",
"      Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006; 12:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/47\">",
"      West DW, Slattery ML, Robison LM, et al. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991; 2:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/48\">",
"      Hardell L, Degerman A, Tomic R, et al. Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. Eur J Cancer Prev 1995; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/49\">",
"      Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/50\">",
"      Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/51\">",
"      Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/52\">",
"      Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/53\">",
"      Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998; 7:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/54\">",
"      Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/55\">",
"      Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998; 9:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/56\">",
"      Lieberman R, Bermejo C, Akaza H, et al. Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology 2001; 58:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/57\">",
"      Lotan Y, Xu XC, Shalev M, et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 2000; 18:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/58\">",
"      Thaller C, Shalev M, Frolov A, et al. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol 2000; 18:3804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/59\">",
"      Urban D, Myers R, Manne U, et al. Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 1999; 35:429.",
"     </a>",
"    </li>",
"    <li>",
"     Price D, Stein B, Goluboff E, et al. Double-blind, placebo-controlled trial of toremifene for the prevention of prostate cancer in men with high-grade prostatic intrapeithelial neoplasia (abstract). J Clin Oncol 2005; 23:106s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/61\">",
"      Taneja SS, Morton R, Barnette G, et al. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 2013; 31:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/62\">",
"      Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10:7727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/63\">",
"      Smith MR, Manola J, Kaufman DS, et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/64\">",
"      Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/65\">",
"      Bylund A, Zhang JX, Bergh A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 2000; 42:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/66\">",
"      Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41736/abstract/67\">",
"      Fleshner NE, Kapusta L, Donnelly B, et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol 2011; 29:2386.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6949 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-F9B63D4400-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41736=[""].join("\n");
var outline_f40_48_41736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Long latency period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Androgen dependency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical trials biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      5-ALPHA REDUCTASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Finasteride",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prostate Cancer Prevention Trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk of high-grade prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dutasteride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Guidelines and regulatory status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12994978\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vitamins and micronutrients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Selenium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Vitamin D analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Toremifene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nonsteroidal antiinflammatory compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19017?source=related_link\">",
"      Chemoprevention in oral dysplasia and head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26937?source=related_link\">",
"      Precancerous lesions of the prostate: Pathology and clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41737="Urinary incontinence in men";
var content_f40_48_41737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary incontinence in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41737/contributors\">",
"     J Quentin Clemens, MD, FACS, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41737/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41737/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/48/41737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9860203\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence in men can be caused by functional abnormalities of the bladder or urethra, particularly in men with prostate disease. Men with urinary incontinence are more likely to report a lower quality of life and are at increased risk of institutionalization compared to men without urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, pathogenesis, evaluation, and management of urinary incontinence in men. Other lower urinary tract symptoms in men, as well as urinary incontinence in women, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7192?source=see_link\">",
"     \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133768727\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief listing of definitions for terms used in this topic follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary incontinence is defined as involuntary leakage of urine.",
"     </li>",
"     <li>",
"      Urge incontinence is involuntary leakage accompanied by urgency. Urgency is the complaint of a sudden and compelling desire to pass urine that is difficult to defer. Commonly-reported precipitants include running water, hand washing, and going out in the cold.",
"     </li>",
"     <li>",
"      Stress incontinence is involuntary leakage with exertion, sneezing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coughing. Leakage may be provoked by minimal or no activity when there is severe urethral sphincter damage.",
"     </li>",
"     <li>",
"      Mixed incontinence is involuntary leakage associated with both urgency and also with exertion, sneezing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coughing.",
"     </li>",
"     <li>",
"      Postvoid dribbling is a term used to describe dribbling of urine retained in the urethra after the bladder has emptied.",
"     </li>",
"     <li>",
"      Incomplete emptying refers to urine that is retained in the bladder after the bladder has attempted to empty.",
"     </li>",
"     <li>",
"      \"Overactive bladder\" is a symptom syndrome consisting of urgency, frequency, and nocturia, with or without urinary incontinence.",
"     </li>",
"     <li>",
"      Lower urinary tract symptoms (LUTS) is a nonspecific term used to refer to any combination of urinary symptoms. An international consensus conference identified LUTS to include symptoms relating to storage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      voiding disturbances. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"       \"Lower urinary tract symptoms in men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete list of terms associated with urinary incontinence is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860210\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of urinary incontinence has been less studied in men compared to women. In general, the prevalence of urinary incontinence in men is approximately half that in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As in women, urinary incontinence rates increase with age, but unlike women, rates continue to increase in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/3\">",
"     3",
"    </a>",
"    ]. Using a definition of at least one urinary incontinence episode in the preceding 12 months among community-dwelling men, the prevalence increases from 4.8 percent in men age 19 to 44 years, to 11.2 percent age 45 to 64 years, to 21.1 percent older than 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence of daily urinary incontinence is 2 to 11 percent in men older than 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/6\">",
"     6",
"    </a>",
"    ]. Prevalence of incontinence does not appear to vary by race or ethnicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of urinary incontinence in men is significantly higher for individuals living in nursing homes (45 to 72 percent) compared to community settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/8\">",
"     8",
"    </a>",
"    ]. Men with urinary incontinence have a higher risk of institutionalization compared to men without urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of specific types of urinary incontinence in men are difficult to ascertain due to the natural history of incontinence being affected by treatment for prostate disease. The distribution of urge incontinence varies between genders, with urge urinary incontinence constituting a much larger portion of total urinary incontinence in men than in women. Mixed incontinence is relatively rare in men, although it is the most common type in women. Men with urge incontinence have a higher rate of depression and are more likely to alter activities (eg, decrease work hours, change employment, or take early voluntary retirement) compared to men who do not have urge incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that the presence of urinary incontinence in men may have a greater emotional and social impact on quality of life compared to women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. Despite the important burden of urinary incontinence in men, only one in five men with symptoms are likely to seek care; men are half as likely as women to seek care for urinary incontinence (22 versus 45 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711967525\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for urge incontinence in men include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Prostate disease, particularly with a history of prostate surgery or radiation therapy",
"     </li>",
"     <li>",
"      History of urinary tract infections",
"     </li>",
"     <li>",
"      Physical limitations, including impairments in activities of daily living",
"     </li>",
"     <li>",
"      Neurologic disease, particularly stroke, spinal cord injury, and impaired cognition",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Sleep apnea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for stress incontinence in men include previous prostate surgery, pelvic trauma, and neurologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860217\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of urinary incontinence depends on the specific type of incontinence. Urinary incontinence is usually due to disease of the lower urinary tract. However, urinary incontinence can also be due to other causes, including medications (",
"    <a class=\"graphic graphic_table graphicRef80413 \" href=\"mobipreview.htm?3/11/3261\">",
"     table 1",
"    </a>",
"    ) or not being able to reach the bathroom in time to urinate as a result of comorbid illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Types of urinary incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are four major types of urinary incontinence associated with lower urinary tract dysfunction: urge incontinence, stress incontinence, mixed incontinence, and incontinence due to incomplete bladder emptying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860226\">",
"    <span class=\"h2\">",
"     Urge incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms responsible for urge incontinence are poorly understood, both in men and women. The etiology of urge incontinence is partly related to uninhibited bladder contractions (also called detrusor overactivity). This may be due to a defect in afferent sensory signaling from the urinary tract, central processing of these signals,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    detrusor muscle dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef62790 \" href=\"mobipreview.htm?22/28/22976\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link&amp;anchor=H1#H1\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860233\">",
"    <span class=\"h2\">",
"     Stress incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress urinary incontinence in men is most commonly due to poor urethral sphincter function. Prostate surgery is the most common cause of stress urinary incontinence in men. It can also occur in those who have had pelvic trauma or a neurologic disorder (eg, traumatic spinal cord injury, spina bifida).",
"   </p>",
"   <p>",
"    The two most frequently performed prostate surgeries leading to stress incontinence are transurethral resection of the prostate (TURP) and radical prostatectomy. TURP involves the resection of obstructing prostate tissue using a cystoscope (",
"    <a class=\"graphic graphic_figure graphicRef58306 \" href=\"mobipreview.htm?13/63/14322\">",
"     figure 2",
"    </a>",
"    ). Damage to the external urethral sphincter can occur during TURP, but this is uncommon; in contemporary series, reported rates of urinary incontinence following TURP are &lt;1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radical prostatectomy is performed to treat prostate cancer. As the external urethral sphincter is closely approximated to the prostatic apex, this structure can be damaged during the surgical dissection (",
"    <a class=\"graphic graphic_figure graphicRef54803 \" href=\"mobipreview.htm?19/35/20023\">",
"     figure 3",
"    </a>",
"    ). Following radical prostatectomy, it is common for men to initially experience stress incontinence. However, this typically improves or resolves over a course of 12 to 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Up to 40 percent of men report some degree of long-term urinary incontinence after radical prostatectomy, but the majority of cases are mild and do not require treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/19\">",
"     19",
"    </a>",
"    ]. The rate of persistent, bothersome urinary incontinence following radical prostatectomy is approximately 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24313?source=see_link&amp;anchor=H24077719#H24077719\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Retropubic prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711968463\">",
"    <span class=\"h2\">",
"     Incomplete emptying (overflow incontinence)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete emptying is a less common cause of incontinence that is due to impaired detrusor contractility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bladder outlet obstruction. A common presentation is nocturnal enuresis (bedwetting) due to pelvic floor relaxation that occurs at night, combined with a very full bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711968224\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is recommended that all women be screened for urinary incontinence, there are no specific evidence-based guidelines for screening in men. Screening recommendations for women are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link&amp;anchor=H1#H1\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is our practice to screen men who have risk factors for urinary incontinence. (See",
"    <a class=\"local\" href=\"#H711967525\">",
"     'Risk factors'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Urinary incontinence screening has been incorporated into health care quality process measures in the United States (US) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/24\">",
"     24",
"    </a>",
"    ]. The following screening questions may identify men with urinary incontinence:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do you ever leak",
"      <span class=\"nowrap\">",
"       urine/water",
"      </span>",
"      when you don't want to?",
"     </li>",
"     <li>",
"      Do you ever leak urine when you cough, laugh, or exercise?",
"     </li>",
"     <li>",
"      Do you ever leak urine on the way to the bathroom?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860240\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history, physical examination, and urinalysis are sufficient to guide initial evaluation of urinary incontinence in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/25\">",
"     25",
"    </a>",
"    ]. The initial evaluation is also helpful in identifying the type of urinary continence (urge, stress, mixed, incomplete emptying), which will direct treatment options. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This initial evaluation should also identify men with &ldquo;complicated urinary incontinence&rdquo; who may need referral to a urologist. (See",
"    <a class=\"local\" href=\"#H148744922\">",
"     'Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711968508\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key components of the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset and temporal course of incontinence",
"     </li>",
"     <li>",
"      Severity",
"     </li>",
"     <li>",
"      Associated symptoms",
"     </li>",
"     <li>",
"      Precipitants",
"     </li>",
"     <li>",
"      Bowel function",
"     </li>",
"     <li>",
"      Sexual function",
"     </li>",
"     <li>",
"      History of prostate disease",
"     </li>",
"     <li>",
"      Comorbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Key components of the history are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Known potentially reversible causes of urinary incontinence should be reviewed with the patient (",
"    <a class=\"graphic graphic_table graphicRef82618 \" href=\"mobipreview.htm?40/13/41179\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A history of previous treatment for prostate disease is also important, as this is a major risk factor for both urge and stress incontinence. If prostate cancer has been previously diagnosed, it is important to be aware of the current tumor status, as this may affect treatment options. As an example, a man with locally advanced prostate cancer would not be a good candidate for artificial sphincter placement. (See",
"    <a class=\"local\" href=\"#H9860291\">",
"     'Surgical treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711968501\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key components of the physical examination are similar for men and women, with a particular focus on the cardiovascular, abdominal, and neurologic examinations. Notable differences in the male examination are listed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncircumcised men should be checked for phimosis and balanitis. The position of the urethral meatus should be noted, as a very proximal position (hypospadias) may cause postvoid dribbling and other bothersome symptoms. After retraction, replace the foreskin in position, to avoid causing paraphimosis. Paraphimosis refers to a retracted foreskin in an uncircumcised or partially circumcised male that cannot be returned to normal position. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=see_link\">",
"     \"Balanitis and balanoposthitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The scrotal skin should be examined for infections or sebaceous cysts. The scrotal contents should be gently palpated to evaluate for masses. The inguinal region should be assessed for the presence of a hernia, since straining in men with partial urinary obstruction can worsen an inguinal hernia. The digital rectal examination is best performed with the patient standing and bent over the examination table, or with the patient in the knee-chest position. Anal sphincter tone, and the presence of rectal masses or fecal impaction should be noted. Prostate size and consistency should also be assessed. The presence of a prostate nodule is an indication for urology referral. The estimation of prostate size by digital examination provides a gross estimate of the degree of benign prostatic, but is less reliable than direct volume measurements with ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414558001\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urinalysis should be performed in all patients, with urine culture if infection is suspected. Urine cytology is indicated only if there is hematuria or risk factors for bladder cancer (eg, extensive smoking history, previous bladder tumor). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of renal function should be obtained if recent results are unavailable.",
"   </p>",
"   <p>",
"    Prostate specific antigen (PSA) testing should be considered in men who present with urinary incontinence. PSA levels may be affected by treatments for prostate disease (eg, 5 alpha reductase inhibitors, prostate surgery). The benefits and risks of PSA testing should be discussed with the patient. Indications for PSA testing in men with lower urinary tract symptoms should be the same as in asymptomatic men, although others would suggest a lower threshold for testing in men with urinary symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\", section on 'Serum prostate specific antigen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for prostate cancer\", section on 'Prostate specific antigen (PSA)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549550\">",
"    <span class=\"h2\">",
"     Additional studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711969076\">",
"    <span class=\"h3\">",
"     Postvoid residual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor bladder emptying may be suspected based on history and examination findings. This can be documented by measuring postvoid residual (PVR) using ultrasound or catheterization. American Urological Association guidelines on benign prostatic hyperplasia recommend against routine PVR testing for men with mild to moderate lower urinary symptoms related to prostatic hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\", section on 'Post-void residual urine volume'",
"    </a>",
"    .) Indications for a PVR include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incontinence associated with severe voiding symptoms in patient with benign prostatic hyperplasia (ie, American Urological Association Index score &ge;20) (",
"      <a class=\"graphic graphic_table graphicRef57680 \" href=\"mobipreview.htm?21/50/22317\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"       \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Overactive bladder symptoms (urgency, frequency, nocturia) without benign prostatic hyperplasia, prior to initiating any antimuscarinic medication (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"       \"Lower urinary tract symptoms in men\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinal cord injury",
"     </li>",
"     <li>",
"      Failed empiric antimuscarinic drug therapy",
"     </li>",
"     <li>",
"      Parkinson and other neurological diseases (except dementia)",
"     </li>",
"     <li>",
"      Recurrent urinary tract infections",
"     </li>",
"     <li>",
"      Detrusor underactivity or bladder outlet obstruction determined by previous urodynamic testing",
"     </li>",
"     <li>",
"      Prior episodes of urinary retention",
"     </li>",
"     <li>",
"      Severe constipation",
"     </li>",
"     <li>",
"      High doses or multiple medications that can suppress detrusor contractility",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase urethral sphincter tone",
"     </li>",
"     <li>",
"      Diabetes mellitus with peripheral neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, a PVR of less than 50 mL is considered adequate emptying, and a PVR greater than 200 mL is considered inadequate and suggestive of either detrusor weakness or obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/29\">",
"     29",
"    </a>",
"    ]. However, a PVR greater than 200 to 300 mL does not in itself require treatment in the absence of symptoms or recurrent infection. Treatment of coexisting conditions (eg, treatment of constipation, stopping drugs that may lead to urinary retention) may reduce PVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711969057\">",
"    <span class=\"h3\">",
"     Urine flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine measurement of the peak urine flow rate with a flowmeter is not necessary. It should only be considered in men with moderate to severe voiding symptoms, especially if invasive therapy is planned. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414558095\">",
"    <span class=\"h3\">",
"     Urodynamic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine urodynamic testing in the evaluation of urinary incontinence is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/30\">",
"     30",
"    </a>",
"    ]. Urodynamics are the physiological diagnostic \"gold standard,\" but are invasive, expensive, require special",
"    <span class=\"nowrap\">",
"     equipment/",
"    </span>",
"    training, and are not usually necessary to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549509\">",
"    <span class=\"h3\">",
"     Bladder diary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a three-day bladder diary can be helpful to document the frequency of urinary incontinence episodes and may be particularly helpful in the assessment of nocturia. In addition, 24-hour pad weights can be used to quantify the degree of incontinence (",
"    <a class=\"graphic graphic_figure graphicRef69130 \" href=\"mobipreview.htm?4/30/4591\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148744922\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with &ldquo;complicated&rdquo; urinary incontinence should be referred to a urologist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior pelvic radiation or surgery",
"     </li>",
"     <li>",
"      Pelvic pain",
"     </li>",
"     <li>",
"      Severe incontinence",
"     </li>",
"     <li>",
"      Severe lower urinary tract symptoms",
"     </li>",
"     <li>",
"      Recurrent urologic infections",
"     </li>",
"     <li>",
"      Neurologic disease",
"     </li>",
"     <li>",
"      Abnormal prostate examination",
"     </li>",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Elevated prostate specific antigen (PSA) level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A urologist may decide to order other tests (eg, cystoscopy, upper urinary tract imaging). As an example, men with postprostatectomy incontinence may have a concomitant bladder neck contracture at the site of the surgical anastomosis between the bladder and urethra, which can be identified by cystoscopy. It is important to treat a bladder neck contracture prior to performing surgery for male stress incontinence, as treatment of the bladder neck contracture is much more complicated after these surgeries. In patients with complicated urinary incontinence, urodynamic testing may identify the etiology of the patient&rsquo;s symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/25\">",
"     25",
"    </a>",
"    ]. The primary goal of such testing is to reproduce the patient&rsquo;s symptoms and to correlate them with objective measures of bladder and urethral function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H637407126\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicomponent approach focused on the patient's most bothersome aspects of urinary incontinence is important for successful management. Treatment aimed at simply decreasing the number of incontinent episodes (the focus of the majority of treatment trials) may not be sufficient to improve the quality of life for patients most bothered by the timing or inconvenience of urinary incontinence, or nocturia.",
"   </p>",
"   <p>",
"    Stepwise treatment strategies should be discussed with the patient. In general, treatment should advance from least invasive to more invasive therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/31\">",
"     31",
"    </a>",
"    ]. In older patients, correcting contributory factors such as comorbid conditions, functional impairment, and medications should be the initial focus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/27\">",
"     27",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    For men with urge, stress, or mixed incontinence, initial treatment follows the same principles as in women, and should include lifestyle advice, behavioral therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of urinary incontinence\", section on 'Lifestyle'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of urinary incontinence\", section on 'Behavioral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of urinary incontinence\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the type of urinary incontinence, it is especially helpful to discuss the goals and expectations of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860247\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies include lifestyle advice (particularly weight loss and dietary changes), bladder training, biofeedback, and pelvic floor muscle exercises. Although evidence demonstrating efficacy is lacking in men, it is reasonable to try nonpharmacologic therapies given their safety, low cost, and proven efficacy in women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of urinary incontinence\", section on 'Lifestyle'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of urinary incontinence\", section on 'Bladder training'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of urinary incontinence\", section on 'Pelvic muscle exercises'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the available research on nonpharmacologic urinary incontinence treatment in men has focused on postsurgical stress incontinence. Two systematic reviews and meta-analyses of randomized trials found that there was no consistent benefit of nonpharmacologic therapies, such as pelvic floor muscle",
"    <span class=\"nowrap\">",
"     therapy/biofeedback",
"    </span>",
"    either pre- or postoperatively, for postsurgical urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/5,32\">",
"     5,32",
"    </a>",
"    ]. Subsequent randomized trials have not found consistent benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 411 men with incontinence six weeks after radical prostatectomy, there was no difference in rates of urinary incontinence between men who received one-to-one pelvic floor muscle training versus control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a similarly-designed trial of 442 patients undergoing transurethral resection of the prostate (TURP), there was also no difference in rates of urinary incontinence between patients receiving training versus control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a trial of 208 men with incontinence for greater than one year after radical prostatectomy, patients were randomly assigned to one of three arms for eight weeks: behavioral therapy alone (pelvic floor muscle training and bladder control strategies), behavioral therapy plus biofeedback and pelvic floor electrical stimulation, or observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/34\">",
"       34",
"      </a>",
"      ]. The number of incontinence episodes decreased for both active interventions (55 and 51 percent reduction respectively), compared to observation (24 percent reduction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For men with postvoid dribbling, management consists of avoidance of urethral compression during voiding (such as from undergarments or pants) and manual &ldquo;milking&rdquo; of the perineal urethra following micturition. Pelvic floor exercises may also be used, although there is no direct evidence of efficacy with any of these interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860254\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic management of urinary incontinence includes alpha blockers, antimuscarinic drugs, and serotonin norepinephrine reuptake inhibitors. This is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860263\">",
"    <span class=\"h3\">",
"     Urge incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimuscarinic drugs are the main pharmacologic agents available for urge incontinence, and alpha blockers are used for men with urge incontinence associated with benign prostatic enlargement.",
"   </p>",
"   <p>",
"    Alpha blockers act to relax smooth muscle of the bladder neck and prostate. In men who have urge incontinence associated with poor bladder emptying, the use of alpha blockers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/15/17653?source=see_link\">",
"     silodosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ) may enhance bladder emptying and improve urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/35\">",
"     35",
"    </a>",
"    ]. These medications are generally well-tolerated; adverse effects vary based on individual alpha blockers. The most important side effects are orthostatic hypotension and dizziness. Adverse effects, efficacy, and titration of specific alpha blockers are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link&amp;anchor=H5#H5\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on 'Alpha-1-adrenergic antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimuscarinic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43733?source=see_link\">",
"     darifenacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/33/39445?source=see_link\">",
"     solifenacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/53/28501?source=see_link\">",
"     fesoterodine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/9/26773?source=see_link\">",
"     trospium",
"    </a>",
"    ) are a mainstay of pharmacologic therapy for urge incontinence. These medications reduce involuntary bladder contractions by affecting afferent signaling and also blocking the muscarinic cholinergic receptors located on the detrusor muscle cell wall. Multiple randomized trials have documented the efficacy of these agents in reducing urge incontinence symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. These studies suggest that symptom improvement is similar across genders. It appears that these medications do not cause a significant increase in postvoid residual volumes when used in men, as previously thought. However, adverse effects from muscarinic receptor blockade may limit drug tolerability and dose escalation. Adverse effects include inhibition of salivary secretion (dry mouth), inhibition of gut motility (constipation), blurred vision, tachycardia, drowsiness, and impaired cognitive function. Adverse effects, contraindications, and efficacy of specific antimuscarinic drugs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of urinary incontinence\", section on 'Antimuscarinics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One randomized trial found that the combination of an alpha blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ) plus an antimuscarinic drug (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    ) was significantly more effective at reducing urge incontinence compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/35\">",
"     35",
"    </a>",
"    ]. Combination therapy appeared to be better than either medication alone, but this did not reach statistical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259219324\">",
"    <span class=\"h4\">",
"     Choosing medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of evidence to guide urge incontinence therapy in men, it is reasonable to initiate pharmacologic treatment with an alpha blocker. Alpha blockers are generally better tolerated than antimuscarinic drugs. If symptoms persist after appropriate titration of an alpha blocker, we suggest the addition of an antimuscarinic drug.",
"   </p>",
"   <p>",
"    The use of alpha blockers and antimuscarinic drugs for lower urinary tract symptoms in men is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860270\">",
"    <span class=\"h3\">",
"     Stress incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;No medications have been approved in the US for the treatment of stress incontinence.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    , a serotonin-norepinephrine reuptake inhibitor, is approved for this indication in many European countries. In the US, duloxetine is only approved for the treatment of major depression and neuropathic pain. Duloxetine stimulates pudendal motor neuron alpha adrenergic and 5-hydroxytryptamine-2 receptors which can improve urinary symptoms.",
"   </p>",
"   <p>",
"    A systematic review of the pharmacologic treatment of male stress incontinence found limited evidence to support the efficacy of any single medication for this indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/37\">",
"     37",
"    </a>",
"    ]. Only one randomized trial was identified which met criteria for high quality evidence. In this randomized trial of 112 men with postprostatectomy stress incontinence, those randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    with pelvic muscle exercises were more likely to report improved incontinence quality of life compared to those randomly assigned to pelvic muscle exercises alone after 16 week follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/38\">",
"     38",
"    </a>",
"    ]. However, this effect quickly disappeared after discontinuation of the medication. Duloxetine was more likely to be discontinued compared to placebo (15 versus 2 percent) during the study period, with nausea being the most commonly cited reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860277\">",
"    <span class=\"h2\">",
"     Adjunctive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive measures include incontinence pads, indwelling catheters, external urinary catheters, and penile incontinence clamps. The treatment of urinary incontinence with an indwelling catheter is usually a poor management choice, as it is associated with urethral trauma, infection, and nephrolithiasis. Incontinence pads and indwelling catheterization are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H36#H36\">",
"     \"Treatment of urinary incontinence\", section on 'Pads and protective garments'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men, external urinary catheters (condom catheters) can be useful in managing urinary incontinence, with less associated morbidity compared to indwelling catheterization. Successful use of an external catheter requires adherence of the condom sheath to the penis. Use of external catheters may not be possible in some patients who are not able to keep catheters in place (eg, due to skin infections) or not physically able to place catheters (eg, obesity, neurologic impairment). In patients with neurogenic bladder dysfunction, the use of an external catheter may be associated with progressive renal damage unless it is confirmed with urodynamics that bladder storage pressures remain low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H6#H6\">",
"     \"Placement and management of urinary bladder catheters\", section on 'External'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another option is the use of a penile incontinence clamp. A clamp is most suitable in ambulatory men with stress incontinence and good bladder storage function. Clamps are meant to be used on an intermittent basis. Their use in men with sensory abnormalities should be avoided, as tissue damage from the clamp can occur with prolonged use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860291\">",
"    <span class=\"h2\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple surgical options are available for patients who do not respond to medical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860300\">",
"    <span class=\"h3\">",
"     Urge incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the minority of patients in whom medical therapy is ineffective for urge incontinence, treatment options include electrical stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], injection of botulinum toxin via cystoscopy, and augmentation cystoplasty. In general, these treatments and their efficacy are similar for men and women. The most common surgical treatment for urge incontinence is sacral nerve stimulation, which is effective for long-term use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/39\">",
"     39",
"    </a>",
"    ]. Adverse events may occur during pre-implantation testing, as well as with permanent lead placement. These include lead migration, pain at the stimulator or lead site, infection, and transient electrical shock. Sacral nerve stimulation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of urinary incontinence\", section on 'Neurologic stimulation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Botulinum toxin injections into the bladder and augmentation cystoplasty are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19336?source=see_link\">",
"     \"Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic complications of spinal cord injury\", section on 'Bladder dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860307\">",
"    <span class=\"h3\">",
"     Stress incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly utilized interventions for male stress incontinence are transurethral bulking agents, perineal slings, and the artificial urinary sphincter. Following radical prostatectomy, it is generally recommended to undergo watchful waiting supplemented with conservative measures for a period of at least 6 to 12 months to allow for spontaneous resolution of stress incontinence symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Men with persistent and bothersome stress urinary incontinence despite conservative management are candidates for surgical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860314\">",
"    <span class=\"h4\">",
"     Transurethral bulking agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various substances can be injected into the submucosal tissues of the urethra or bladder neck to improve stress incontinence symptoms. Some observational studies have found injection of collagen to be modestly effective in treating urinary incontinence due to benign prostatic hyperplasia or following prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The success rates in men are lower than those reported in women, presumably due to increased scarring at the bladder neck following prostate surgery. In men, multiple injections (up to four) are usually required to achieve satisfactory results, which generally last one year or less, at which point an additional injection is required. The injections are typically performed with intravenous sedation in men, while in women it is common to utilize only local anesthesia. Reported success rates range from 36 to 69 percent, but few men are completely dry after this therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860321\">",
"    <span class=\"h4\">",
"     Perineal slings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As sling techniques involving passive urethral compression have been successfully employed in the treatment of female stress incontinence for several years, similar techniques have been adapted for use in men. A perineal bone-anchored sling technique is the most common sling technique used to treat male stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At short-term follow-up (&lt;12 months), stress incontinence cure rates following perineal bone-anchored sling placement are 60 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/45\">",
"     45",
"    </a>",
"    ]. Long-term data are lacking, but one study at 48 month follow-up reported a cure rate of 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/46\">",
"     46",
"    </a>",
"    ]. Success rates are relatively poor in men with severe stress incontinence symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], and it is commonly accepted that this technique should be limited to men with mild to moderate leakage. Complications include wound infection (0 to 6 percent), urethral erosion (0 to 2 percent), and transient perineal pain or numbness (16 to 72 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/46,48,49\">",
"     46,48,49",
"    </a>",
"    ]. Postoperative urodynamic studies following male sling placement have not found significant obstructive voiding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In general, complications following sling placement appear to be lower than those seen following artificial urinary sphincter placement.",
"   </p>",
"   <p>",
"    The International Consultation on Incontinence (ICI) and the United Kingdom National Institute for Health and Clinical Excellence (NICE) have concluded that the current evidence supports the safety and efficacy of male slings for postprostatectomy stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/41,52\">",
"     41,52",
"    </a>",
"    ]. However, more data are needed to confirm the long-term efficacy of perineal slings.",
"   </p>",
"   <p>",
"    A newer male sling technique has been described which involves placement of a mesh sling transversely through the obturator foramen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. This technique is analogous to &lsquo;transobturator slings&rsquo; which are used for female stress incontinence. Studies of this technique are limited to small numbers of patients with short follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860328\">",
"    <span class=\"h4\">",
"     Artificial urinary sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The artificial urinary sphincter has been recognized for many years as the most effective long-term treatment for men with severe stress incontinence. The artificial urinary sphincter consists of three silicone components: a cuff, a balloon reservoir, and a pump. Each of these components is attached to a length of silicone tubing and connected together during the surgical implant procedure.",
"   </p>",
"   <p>",
"    Success rates (use of &le;one pad daily) have ranged from 59 to 90 percent at follow-up intervals ranging from one to eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/41\">",
"     41",
"    </a>",
"    ]. Patient satisfaction with this technique is high, even among men with severe stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Postoperative wound infection, which occurs in &lt;3 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/45\">",
"     45",
"    </a>",
"    ], can be a disastrous complication as this typically requires removal of the entire device. Urethral erosion of the cuff can also occur. A common cause of late urethral erosion is Foley catheter trauma.",
"   </p>",
"   <p>",
"    After artificial urinary sphincter placement, it is vital that urethral instrumentation be kept to a minimum, as such instrumentation may weaken the urethra at the cuff site and cause erosion of the cuff. If catheterization is required, the artificial urinary sphincter must be deactivated, often requiring involvement of a urologist. Teaching the patient to deactivate the device may be useful, as the patient may be able to take responsibility for deactivating it prior to Foley catheter placement.",
"   </p>",
"   <p>",
"    When urethral erosion occurs, the cuff must be surgically removed and a Foley catheter placed for a period of two weeks to allow the urethra to heal. Another cuff may then be placed at a later time. To maintain long-term continence, surgical revision of the artificial urinary sphincter is often required. Revisions may be required due to infection, urethral erosion, mechanical malfunction of the device (eg, leak of fluid), or urethral atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860356\">",
"    <span class=\"h4\">",
"     Choosing a procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;For select men with mild stress incontinence or those who are not candidates for more invasive surgery, transurethral bulking agents may be a reasonable treatment option. Prior injection of bulking agents does not appear to affect the postoperative results of male perineal slings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/59\">",
"     59",
"    </a>",
"    ] or artificial urinary sphincters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most men with persistent and bothersome stress incontinence, the main treatment decision involves choosing between the sling and artificial urinary sphincter. Slings may be preferred in men with limited manual dexterity who may have difficulty manipulating the artificial urinary sphincter, or in those with more mild incontinence. The artificial urinary sphincter is typically a better choice for men with previous pelvic radiation therapy or severe incontinence. Of note, previous artificial urinary sphincter explantation is associated with a high rate of sling failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/48,50\">",
"     48,50",
"    </a>",
"    ], while previous sling placement does not appear to affect the outcome of artificial urinary sphincter placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/61\">",
"     61",
"    </a>",
"    ]. For many men, the decision between an artificial urinary sphincter and a perineal sling is ultimately based on patient preference. There are data to suggest that most men prefer a sling if given the choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41737/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/9/35987?source=see_link\">",
"       \"Patient information: Urinary incontinence in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9860363\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of urinary incontinence in men is approximately half that of women. Although men may experience significant emotional and social impact on quality of life, incontinent men are half as likely as women to seek care for urinary incontinence. (See",
"      <a class=\"local\" href=\"#H9860210\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men who have risk factors for urinary incontinence (advanced age, prostate disease, history of urinary tract infections, physical limitations, neurologic disease, constipation, depression, or diabetes) should be asked if they have had episodes of incontinence. (See",
"      <a class=\"local\" href=\"#H711968224\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H711967525\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A history, physical examination, and urinalysis are sufficient to guide initial therapy. Men with &ldquo;complicated&rdquo; urinary incontinence should be referred to an urologist. Complicated urinary incontinence includes those with prior pelvic radiation or surgery, pelvic pain, severe incontinence symptoms, severe lower urinary tract symptoms, recurrent urologic infections, neurologic disease, abnormal prostate examination, hematuria, or elevated prostate specific antigen. (See",
"      <a class=\"local\" href=\"#H9860240\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A multicomponent approach focused on the patient's most bothersome aspects of urinary incontinence is important for successful management. Treatment should start with the least invasive therapies, which include weight loss, dietary changes, pelvic floor muscle exercises, and medications. Contributory factors such as comorbid conditions and functional impairment should be corrected when possible, especially in older patients. (See",
"      <a class=\"local\" href=\"#H637407126\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with urge incontinence who do not respond to lifestyle interventions or pelvic floor muscle exercise, we recommend treatment with either an alpha blocker or antimuscarinic medication (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Because of fewer adverse effects, we suggest initiating treatment with an alpha blocker rather than an antimuscarinic medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If urge incontinence symptoms persist despite adequate titration of alpha blocker therapy, we suggest addition of an antimuscarinic medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9860263\">",
"       'Urge incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with stress incontinence who do not respond to pelvic floor muscle exercise, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9860270\">",
"       'Stress incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical treatments for urinary incontinence are reserved for patients who do not respond to medical management. Sacral nerve stimulation, botulinum toxin injections, and augmentation cystoplasty are used for treatment of urge incontinence. Transurethral bulking agent injections, perineal slings, and artificial urinary sphincters are used to treat stress incontinence. (See",
"      <a class=\"local\" href=\"#H9860291\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/1\">",
"      Tennstedt SL, Chiu GR, Link CL, et al. The effects of severity of urine leakage on quality of life in Hispanic, white, and black men and women: the Boston community health survey. Urology 2010; 75:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/2\">",
"      Harris SS, Link CL, Tennstedt SL, et al. Care seeking and treatment for urinary incontinence in a diverse population. J Urol 2007; 177:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/3\">",
"      Buckley BS, Lapitan MC, Epidemiology Committee of the Fourth International Consultation on Incontinence, Paris, 2008. Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. Urology 2010; 76:265.",
"     </a>",
"    </li>",
"    <li>",
"     Stothers L, Thom DH, Calhoun EA. Urinary incontinence in men. In: Urologic Diseases in America, Litwin MS, Saigal CS.  (Eds). US Department of Health and Human Service, National Institutes of Health, National Institute of Diabetes and Kigestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2007: p. 193. Available at: file://kidney.niddk.nih.gov/statistics/uda/Urologic_Diseases_in_America.pdf (Accessed on September 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/5\">",
"      Shamliyan TA, Wyman JF, Ping R, et al. Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol 2009; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/6\">",
"      Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/7\">",
"      Tennstedt SL, Link CL, Steers WD, McKinlay JB. Prevalence of and risk factors for urine leakage in a racially and ethnically diverse population of adults: the Boston Area Community Health (BACH) Survey. Am J Epidemiol 2008; 167:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/8\">",
"      Sahyoun NR, Pratt LA, Lentzner H, et al. The changing profile of nursing home residents: 1985-1997. Aging Trends 2001; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/9\">",
"      Bazt&aacute;n JJ, Arias E, Gonz&aacute;lez N, Rodr&iacute;guez de Prada MI. New-onset urinary incontinence and rehabilitation outcomes in frail older patients. Age Ageing 2005; 34:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/10\">",
"      Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006; 97:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/11\">",
"      Lagro-Janssen TA, Hilkens CJ, Klaasen RI, Teunissen D. Greater emotional and social effect of urinary incontinence in men than women. J Am Geriatr Soc 2008; 56:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/12\">",
"      Rieken M, Ebinger Mundorff N, Bonkat G, et al. Complications of laser prostatectomy: a review of recent data. World J Urol 2010; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/13\">",
"      Thiel DD, Petrou SP. Electroresection and open surgery. Urol Clin North Am 2009; 36:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/14\">",
"      Lerner LB, Tyson MD. Holmium laser applications of the prostate. Urol Clin North Am 2009; 36:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/15\">",
"      Loughlin KR, Prasad MM. Post-prostatectomy urinary incontinence: a confluence of 3 factors. J Urol 2010; 183:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/16\">",
"      Hammerer P, Huland H. Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy. J Urol 1997; 157:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/17\">",
"      Donnellan SM, Duncan HJ, MacGregor RJ, Russell JM. Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology 1997; 49:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/18\">",
"      Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/19\">",
"      Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/20\">",
"      Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005; 173:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/21\">",
"      Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/22\">",
"      Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/23\">",
"      Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283:354.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid Services. https://www.cms.gov/PQRS/ (Accessed on September 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/25\">",
"      Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29:213.",
"     </a>",
"    </li>",
"    <li>",
"     Staskin D, Hilton P, Emmanuel A, et al.. Initial assessment of incontinence. In: Incontinence, 3rd ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications, Plymouth, UK 2005. p.485.",
"    </li>",
"    <li>",
"     DuBeau CE, Kuchel GA, Johnson T, et al.. Incontinence in the frail elderly. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications Ltd, Paris 2009. p.961.",
"    </li>",
"    <li>",
"     American Urological Association Guidelines. www.auanet.org/guidelines (Accessed on September 28, 2011).",
"    </li>",
"    <li>",
"     Fantl JA, Newman DK, Colling J, et al.. Urinary Incontinence in Adults: Acute and Chronic Management, Clinical Practice Guideline, No. 2. AHCPR Publication No. 96-0682, Public Health and Human Service, Agency for Health Care Policy and Research, Rockville, MD 1966.",
"    </li>",
"    <li>",
"     Griffiths D, Kondo, Bauer S, et al.. Dynamic testing. In: Incontinence, 3rd ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications, Plymouth, UK 2005. p.587.",
"    </li>",
"    <li>",
"     Management Recommendations. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications, Paris 2009. p.1774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/32\">",
"      Hunter KF, Glazener CM, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2007; :CD001843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/33\">",
"      Glazener C, Boachie C, Buckley B, et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet 2011; 378:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/34\">",
"      Goode PS, Burgio KL, Johnson TM 2nd, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA 2011; 305:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/35\">",
"      Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/36\">",
"      Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; :CD003781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/37\">",
"      Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. Eur Urol 2008; 53:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/38\">",
"      Filocamo MT, Li Marzi V, Del Popolo G, et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur Urol 2007; 51:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/39\">",
"      van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/40\">",
"      Yamanishi T, Mizuno T, Watanabe M, et al. Randomized, placebo controlled study of electrical stimulation with pelvic floor muscle training for severe urinary incontinence after radical prostatectomy. J Urol 2010; 184:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/41\">",
"      Herschorn S, Bruschini H, Comiter C, et al. Surgical treatment of stress incontinence in men. Neurourol Urodyn 2010; 29:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/42\">",
"      Bauer RM, Bastian PJ, Gozzi C, Stief CG. Postprostatectomy incontinence: all about diagnosis and management. Eur Urol 2009; 55:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/43\">",
"      Smith DN, Appell RA, Rackley RR, Winters JC. Collagen injection therapy for post-prostatectomy incontinence. J Urol 1998; 160:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/44\">",
"      Westney OL, Bevan-Thomas R, Palmer JL, et al. Transurethral collagen injections for male intrinsic sphincter deficiency: the University of Texas-Houston experience. J Urol 2005; 174:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/45\">",
"      Comiter CV. Surgery Insight: surgical management of postprostatectomy incontinence--the artificial urinary sphincter and male sling. Nat Clin Pract Urol 2007; 4:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/46\">",
"      Comiter CV. The male perineal sling: intermediate-term results. Neurourol Urodyn 2005; 24:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/47\">",
"      Onur R, Singla A. Comparison of bone-anchored male sling and collagen implant for the treatment of male incontinence. Int J Urol 2006; 13:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/48\">",
"      Castle EP, Andrews PE, Itano N, et al. The male sling for post-prostatectomy incontinence: mean followup of 18 months. J Urol 2005; 173:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/49\">",
"      Fischer MC, Huckabay C, Nitti VW. The male perineal sling: assessment and prediction of outcome. J Urol 2007; 177:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/50\">",
"      Ullrich NF, Comiter CV. The male sling for stress urinary incontinence: urodynamic and subjective assessment. J Urol 2004; 172:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/51\">",
"      Clemens JQ, Bushman W, Schaeffer AJ. Urodynamic analysis of the bulbourethral sling procedure. J Urol 1999; 162:1977.",
"     </a>",
"    </li>",
"    <li>",
"     Suberethral synthetic sling insertion for stress urinary incontinence in men. National Institute for Health and Clinical Excellence. file://guidance.nice.org.uk/IPG256 (Accessed on September 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/53\">",
"      Rehder P, Gozzi C. Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. Eur Urol 2007; 52:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/54\">",
"      Bauer RM, Mayer ME, Gratzke C, et al. Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year. Eur Urol 2009; 56:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/55\">",
"      Davies TO, Bepple JL, McCammon KA. Urodynamic changes and initial results of the AdVance male sling. Urology 2009; 74:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/56\">",
"      Fleshner N, Herschorn S. The artificial urinary sphincter for post-radical prostatectomy incontinence: impact on urinary symptoms and quality of life. J Urol 1996; 155:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/57\">",
"      Haab F, Trockman BA, Zimmern PE, Leach GE. Quality of life and continence assessment of the artificial urinary sphincter in men with minimum 3.5 years of followup. J Urol 1997; 158:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/58\">",
"      Litwiller SE, Kim KB, Fone PD, et al. Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. J Urol 1996; 156:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/59\">",
"      Comiter CV. The male sling for stress urinary incontinence: a prospective study. J Urol 2002; 167:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/60\">",
"      Gomes CM, Broderick GA, S&aacute;nchez-Ortiz RF, et al. Artificial urinary sphincter for post-prostatectomy incontinence: impact of prior collagen injection on cost and clinical outcome. J Urol 2000; 163:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/61\">",
"      Fisher MB, Aggarwal N, Vuruskan H, Singla AK. Efficacy of artificial urinary sphincter implantation after failed bone-anchored male sling for postprostatectomy incontinence. Urology 2007; 70:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41737/abstract/62\">",
"      Kumar A, Litt ER, Ballert KN, Nitti VW. Artificial urinary sphincter versus male sling for post-prostatectomy incontinence--what do patients choose? J Urol 2009; 181:1231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14611 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41737=[""].join("\n");
var outline_f40_48_41737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9860363\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9860203\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133768727\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9860210\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711967525\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9860217\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9860226\">",
"      Urge incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9860233\">",
"      Stress incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711968463\">",
"      Incomplete emptying (overflow incontinence)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H711968224\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9860240\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711968508\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711968501\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414558001\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549550\">",
"      Additional studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711969076\">",
"      - Postvoid residual",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711969057\">",
"      - Urine flow rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414558095\">",
"      - Urodynamic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H549509\">",
"      - Bladder diary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148744922\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H637407126\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9860247\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9860254\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9860263\">",
"      - Urge incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H259219324\">",
"      Choosing medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9860270\">",
"      - Stress incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9860277\">",
"      Adjunctive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9860291\">",
"      Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9860300\">",
"      - Urge incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9860307\">",
"      - Stress incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9860314\">",
"      Transurethral bulking agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9860321\">",
"      Perineal slings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9860328\">",
"      Artificial urinary sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9860356\">",
"      Choosing a procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9860363\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14611|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/28/22976\" title=\"figure 1\">",
"      Physiology normal micturition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/63/14322\" title=\"figure 2\">",
"      TURP result",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/35/20023\" title=\"figure 3\">",
"      Prostate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/30/4591\" title=\"figure 4\">",
"      Voiding diary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14611|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/11/3261\" title=\"table 1\">",
"      Meds that worsen UI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/13/41179\" title=\"table 2\">",
"      Reversible cause incontinence A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/50/22317\" title=\"table 3\">",
"      International Prostate Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=related_link\">",
"      Balanitis and balanoposthitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7192?source=related_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=related_link\">",
"      Paraphimosis: Definition, pathophysiology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/9/35987?source=related_link\">",
"      Patient information: Urinary incontinence in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19336?source=related_link\">",
"      Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41738="Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency";
var content_f40_48_41738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41738/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41738/contributors\">",
"     Jaime R Merchan, MD, MMSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41738/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/48/41738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/48/41738/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/48/41738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of renal disease and electrolyte disorders can result from the drugs that are used to treat malignant disease. Chemotherapeutic agents can affect the glomerulus, tubules, interstitium or the renal microvasculature, with clinical manifestations that range from an asymptomatic elevation of serum creatinine to acute renal failure requiring dialysis.",
"   </p>",
"   <p>",
"    The kidneys are a major elimination pathway for many antineoplastic drugs and their metabolites. Renal impairment can result in delayed drug excretion and metabolism of chemotherapeutic agents, resulting in increased systemic toxicity. Many drugs require dose adjustment when administered in the setting of renal insufficiency (",
"    <a class=\"graphic graphic_table graphicRef56245 \" href=\"mobipreview.htm?1/42/1708\">",
"     table 1",
"    </a>",
"    ). Minimizing nonrenal systemic toxicity may be a particular problem in patients on chronic hemodialysis, especially when the details of drug elimination and metabolism are not fully known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nephrotoxicity of different chemotherapy agents, preventive strategies, and recommended dose modifications in patients with renal insufficiency will be reviewed here. An overview of renal diseases associated with various cancers (including paraneoplastic syndromes), and the renal complications of tumor lysis syndrome and hematopoietic cell transplantation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=see_link\">",
"     \"Overview of renal disease associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTIMATION OF GFR FOR POSSIBLE DOSE ADJUSTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two principal pathways for drug excretion by the kidney: glomerular filtration and tubular secretion. Glomerular filtration plays a major role with non-protein-bound small molecules (ie, of a size that can pass through the glomerular capillary wall). Such molecules cannot be filtered if they are protein-bound in the circulation; these drugs, if they are renally excreted, enter the urine by secretion in the proximal tubule.",
"   </p>",
"   <p>",
"    For those drugs in which renal excretion is an important determinant of elimination of the intact drug or an active metabolite, dose adjustment is often required if renal function is impaired. For chemotherapeutic drugs, measurement of serum drug concentrations is not usually performed. Dose adjustment in this setting is typically based upon two factors: an estimation of glomerular filtration rate (GFR), which serves as an index of the number of functioning nephrons, and evaluation of clinical signs of drug toxicity (eg, neutropenia, thrombocytopenia).",
"   </p>",
"   <p>",
"    Estimation equations (eg, Cockcroft-Gault, MDRD, and CKD-EPI) based upon a stable serum creatinine concentration also correlate with the measured GFR. They are now the most common method used in routine clinical practice due primarily to convenience. A creatinine clearance calculation based upon a 24-hour collection of urine is cumbersome and subject to error due to incomplete urine collection. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR NEPHROTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors can potentiate renal dysfunction and contribute to the nephrotoxic potential of antineoplastic drugs. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravascular volume depletion, either due to external losses or fluid sequestration (as in ascites or edema). This is one of the most common factors contributing to the nephrotoxic potential of antineoplastic drugs.",
"     </li>",
"     <li>",
"      The concomitant use of nonchemotherapeutic nephrotoxic drugs (eg, aminoglycoside antibiotics, nonsteroidal antiinflammatory drugs) or radiographic ionic contrast media in patients with or without preexisting renal dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary tract obstruction secondary to underlying tumor.",
"     </li>",
"     <li>",
"      Intrinsic renal disease that is idiopathic, related to other comorbidities, or to the cancer itself. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=see_link\">",
"       \"Overview of renal disease associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263265423\">",
"    <span class=\"h1\">",
"     DRUG HANDLING IN DIALYSIS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing dialysis, two issues must be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the kidneys are no longer functioning, dose reduction may be needed to avoid overexposure and drug toxicity.",
"     </li>",
"     <li>",
"      Drug clearance by dialysis must be taken into account for appropriate timing of chemotherapy in patient treated with hemodialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those drugs in which a substantial fraction is removed by hemodialysis, chemotherapy should be administered after dialysis to avoid drug removal and loss of efficacy. On the other hand, for drugs that are not significantly removed by dialysis, administration is not related to the timing of dialysis.",
"   </p>",
"   <p>",
"    Partial dialysis removal may be used to improve drug tolerance. As an example, dialysis sessions may be started at a certain time following administration of a drug like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    to remove the drug that has not been distributed to its site of action but may still contribute to side effects.",
"   </p>",
"   <p>",
"    Data on management of cytotoxic chemotherapy drugs and combination regimens in patients undergoing dialysis are scant, and consist mainly of single case reports. Proposed guidelines for dose adjustment and timing of cytotoxic drug administration in patients undergoing hemodialysis are available from several groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. When known, dosing guidelines for individual drugs in patients undergoing dialysis are available through the Lexicomp drug database in UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CYTOTOXIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapeutic agents can cause nephrotoxicity by a variety of mechanisms (",
"    <a class=\"graphic graphic_table graphicRef54722 \" href=\"mobipreview.htm?28/4/28749\">",
"     table 2",
"    </a>",
"    ). While many drugs induce a fall in the GFR that is dose-related and predictable, others are associated with a more protracted decline in renal function, which is often irreversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is one of the most commonly used antineoplastic drugs, but it is also one of the most nephrotoxic. Cisplatin-induced renal insufficiency is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal approach to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    therapy in patients with preexisting renal impairment is unknown. Clinical trial protocols often require a serum creatinine less than 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or a creatinine clearance of &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for administration of the full dose of cisplatin and exclude patients with more significant renal impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/5\">",
"     5",
"    </a>",
"    ]. This restriction is probably related more to concerns regarding increased nonrenal toxicity (ototoxicity, neuropathy) than to an increased risk of acute renal failure.",
"   </p>",
"   <p>",
"    The manufacturer recommends that repeat courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    should not be given unless or until serum creatinine is &lt;1.5",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mL",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BUN is &lt;25",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mL. There are no FDA-approved renal dosing adjustment guidelines. Empiric guidelines have suggested cisplatin can be administered to patients with renal impairment with dose reduction, although extensive data supporting such recommendations are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As an example, one recommendation suggests a 25 percent dose reduction for a creatinine clearance of 46 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a 50 percent dose reduction for a creatinine clearance of 31 to 45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6\">",
"     6",
"    </a>",
"    ]. Others have recommended cisplatin can be administered to patients with even more severe renal impairment (see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     \"Cisplatin: Drug information\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the available data are scant and predominantly comprised of single case reports, combinations containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    have been successfully administered to patients undergoing hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both experimental and clinical studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is significantly less nephrotoxic than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This increase in safety may reflect the enhanced stability of carboplatin, which has carboxylate and cyclobutane moieties in the cis position, rather than chloride [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/12\">",
"     12",
"    </a>",
"    ]. Hypomagnesemia appears to be the most common manifestation of nephrotoxicity, although it occurs less often than with cisplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute renal failure has been reported, particularly in patients previously treated with several courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/12\">",
"     12",
"    </a>",
"    ]. Direct tubular injury leading to acute tubular necrosis is the primary mechanism. A less common renal side effect is renal magnesium wasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy regimens incorporating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    have been successfully used in patients undergoing hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/17-22\">",
"     17-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     AUC dose calculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of renal clearance to the metabolism and excretion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is emphasized by its usual dosing schema, which is based upon an estimate of the GFR and the desired level of drug exposure, according to the area under the curve of concentration X time (AUC,",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    x min), rather than the more common dosing calculation based upon the body surface area",
"    <span class=\"nowrap\">",
"     (mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"   </p>",
"   <p>",
"    Using",
"    the desired target AUC (which typically varies between 5 and 7",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    x min) and the estimated GFR, the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is then calculated by use of the Calvert formula: Total carboplatin dose, mg = Target AUC X (estimated creatinine clearance + 25). Because of potential changes in weight or renal function, this calculation should be repeated prior to each administered course of carboplatin.",
"   </p>",
"   <p>",
"    The Calvert formula was developed based upon accurate measurement of GFR using the clearance of 51-Chromium-labeled EDTA (51-Cr EDTA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/23\">",
"     23",
"    </a>",
"    ]. In most cases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    dosing is based upon an estimation of the GFR using the serum creatinine, and calculated according to the Cockcroft-Gault equation (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians (particularly in the field of gynecologic oncology) have preferred to estimate the creatinine clearance using the Jelliffe formula, which is not based upon weight or body surface area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. This is because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    dosing was based upon the Jelliffe formula in many of the trials that established carboplatin treatment for gynecologic cancers. However, in February 2011, the Gynecologic Oncology Group (GOG) changed their policies for carboplatin dose calculation to recommend that estimated creatinine clearance be calculated by the Cockcroft-Gault method in all patients.",
"   </p>",
"   <p>",
"    The following issues are relevant to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    dose calculation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Total",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      <strong>",
"       dose is calculated in mg, NOT",
"       <span class=\"nowrap\">",
"        mg/m",
"       </span>",
"      </strong>",
"      <strong>",
"       <sup>",
"        2",
"       </sup>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Maximum GFR",
"      </strong>",
"      &ndash; The accuracy of dosing using a calculated rather than a directly measured GFR has been questioned [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/28\">",
"       28",
"      </a>",
"      ]. Nevertheless, this is a standard approach.",
"      <br/>",
"      <br/>",
"      When using an estimate instead of direct measurement of the GFR to calculate the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      dose using the Calvert formula, calibration of the creatinine assay may impact dosing. In the US, as of the end of 2010, all laboratories must use a creatinine method that has calibration that is traceable to an Isotope Dilution Mass Spectrometry (IDMS) reference measurement procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/29\">",
"       29",
"      </a>",
"      ]. However, this gives lower creatinine results than the older measurement procedures used to derive the Calvert formula, and hence, higher estimates of the GFR. This could result in higher calculated carboplatin doses and may potentially result in increased toxicities.",
"      <br/>",
"      <br/>",
"      The GOG now recommends that creatinine clearance be estimated using a minimum value for serum creatinine of 0.7",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      Furthermore, if an estimated GFR based upon measured serum creatinine is used in the Calvert formula, the FDA recommends limiting the maximal GFR&nbsp;for the calculation to 125",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/30\">",
"       30",
"      </a>",
"      ]. This recommendation does not apply if the GFR is directly measured. The GOG has now mandated a similar cap for patients on their&nbsp;carboplatin trials&nbsp;(including trials conducted in the setting of potentially curable disease).&nbsp;",
"      <br/>",
"      <br/>",
"      For practical purposes, this means that maximal allowed doses of carboplatin are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      AUC 6 = 900 mg",
"     </li>",
"     <li>",
"      AUC 5 = 750 mg",
"     </li>",
"     <li>",
"      AUC 4 = 600 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Obese patients",
"      </strong>",
"      &ndash; Another point of unresolved controversy is the appropriate weight to use when calculating the estimated GFR. The original Cockcroft-Gault formula to estimate GFR used actual body weight, but none of the patients was obese. Most clinicians use actual body weight in the Cockcroft-Gault formula for nonobese patients, although institutional practice varies. However, the use of actual body weight in the Cockcroft-Gault calculation can result in an overestimate of the GFR and a higher than needed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      dose in obese individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The best weight descriptor to use for overweight or obese patients is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Among the methods suggested to calculate the appropriate dose of carboplatin in obese patients are the use of adjusted rather than actual body weight to calculate the GFR (as recommended by the GOG) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/32,33\">",
"       32,33",
"      </a>",
"      ], use of the Jelliffe formula (which is not based upon weight or body surface area), and the use of a flat dosing strategy based upon an estimate of the population carboplatin clearance (140",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      for overweight patients with normal renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/32\">",
"       32",
"      </a>",
"      ]. As an example, if a carboplatin AUC of 5 mg",
"      <span class=\"nowrap\">",
"       min/mL",
"      </span>",
"      is desired, an appropriate dose would by 5 x 140 = 700 mg.",
"      <br/>",
"      <br/>",
"      The GOG recommends that actual weight be used for estimation of the GFR when using the Cockcroft-Gault equation as long as patients have a body mass index of &lt;25 (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). For other patients, use of an adjusted weight is suggested (adjusted weight (kg) = ((actual weight - ideal weight) x 0.40) + ideal weight). A calculator for ideal body weight is available (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=see_link\">",
"       calculator 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , clinically significant renal toxicity, such as acute tubular necrosis, is rare but does occur with the third generation platinum compound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , sometimes in the setting of an immune-mediated intravascular hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Limited data with oxaliplatin suggests no exacerbation of preexisting mild renal impairment during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is predominantly cleared by the kidneys. Oxaliplatin doses up to 130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks have been well tolerated in patients with mild to moderate renal dysfunction (creatinine clearance above 20",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and dose reduction appears not to be necessary in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/39\">",
"     39",
"    </a>",
"    ]. The US FDA-approved labeling suggests a reduced starting dose in patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    while Canadian guidelines recommend avoiding the drug in such patients. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     \"Oxaliplatin: Drug information\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Some experts recommend dose reduction in patients with ESRD undergoing hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2\">",
"     2",
"    </a>",
"    ], although others suggest this is not necessary if hemodialysis is performed shortly after drug administration, and the dosing interval is extended to three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Alkylating agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10242529\">",
"    <span class=\"h3\">",
"     Bendamustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"     Bendamustine",
"    </a>",
"    is an alkylating agent that is used for treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Moderate renal impairment (CrCl 40 to 80",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    does not appear to alter pharmacokinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/41\">",
"     41",
"    </a>",
"    ]. However, bendamustine has not been studied in patients with CrCL &lt;40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and the",
"    <a class=\"external\" href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d53698-57fa-7c99-fc5b-f52a55684826\">",
"     US FDA-approved manufacturer&rsquo;s package insert",
"    </a>",
"    recommends that bendamustine not be used in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main urologic toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is hemorrhagic cystitis. The primary renal effect of cyclophosphamide is hyponatremia, which is due to an increased effect of antidiuretic hormone (ADH), impairing the kidney's ability to excrete water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Chemotherapy-induced nausea may also play a contributory role, since nausea is a potent stimulus to ADH release. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link\">",
"     \"Cystitis in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link&amp;anchor=H12#H12\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\", section on 'Other factors affecting ADH secretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia is usually seen in patients receiving high doses of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (eg, 30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 6",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in the setting of hematopoietic stem cell transplantation). Although less common, hyponatremia can also occur with oral therapy or with lower intravenous doses (eg, 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    that are given as pulse therapy in autoimmune diseases such as lupus nephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia typically occurs acutely and resolves within approximately 24 hours after discontinuation of the drug. Hyponatremia poses a particular problem for patients undergoing high dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , who are often fluid loaded to prevent hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/44\">",
"     44",
"    </a>",
"    ]. The combination of increased ADH effect and enhanced water intake can lead to severe, occasionally fatal hyponatremia within 24 hours. This complication can be minimized by using isotonic saline rather than hypotonic solutions to maintain a high urine output. However, hyponatremia can worsen even with isotonic saline administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Therapies to raise the serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for dose reduction for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in patients with renal insufficiency is controversial. Dose adjustment is not recommended by several authors who have shown no association between renal function and either cyclophosphamide clearance or hematologic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,45\">",
"     6,45",
"    </a>",
"    ]. In the United States, the Food and Drug Administration (US FDA)-approved labeling for cyclophosphamide states that there is no consistent evidence to indicate a need for reduced doses in patients with renal function impairment.",
"   </p>",
"   <p>",
"    However, others have suggested the need for dose adjustment in patients with marked renal insufficiency (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/46\">",
"     46",
"    </a>",
"    ]. Some authors advocate a 25 percent dose reduction in patients with creatinine clearance &lt;10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ], while others have suggested only a 10 and 20 percent dose reduction for patients with creatinine clearance values less than 55 and 20",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/47\">",
"     47",
"    </a>",
"    ]. Guidelines from Cancer Care Ontario for management of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    suggest a 25 to 50 percent reduction in dose in patients with mild to moderate renal impairment (&lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with end stage renal disease,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is moderately hemodialyzable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/16/27909?source=see_link\">",
"     \"Drug removal during continuous renal replacement therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , the predominant toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    on the urinary tract is hemorrhagic cystitis. Ifosfamide can also cause SIADH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link\">",
"     \"Cystitis in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, nephrotoxicity is more likely with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Ifosfamide nephrotoxicity affects the proximal renal tubule and is characterized by one or more of the following signs of acute tubular dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metabolic acidosis with a normal anion gap (hyperchloremic acidosis) due to type 1 (distal) or type 2 (proximal) renal tubular acidosis",
"     </li>",
"     <li>",
"      Hypophosphatemia induced by decreased proximal phosphate reabsorption, which can lead to rickets in children",
"     </li>",
"     <li>",
"      Renal glucosuria, aminoaciduria, and a marked increase in beta-2-microglobulin excretion, all from generalized proximal dysfunction",
"     </li>",
"     <li>",
"      Polyuria due to nephrogenic diabetes insipidus",
"     </li>",
"     <li>",
"      Hypokalemia, which may be severe, resulting from increased urinary potassium losses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data on tubular dysfunction come predominantly from pediatric patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . There are few data on long-term renal function in adults who have received ifosfamide. However, a persistent decline in GFR over time has been described after as little as one course of ifosfamide in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/50\">",
"     50",
"    </a>",
"    ]. Nephrotoxicity due to ifosfamide is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14806?source=see_link\">",
"     \"Ifosfamide nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pre-existing renal disease is a risk factor for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity. The FDA-approved labeling does not contain dosage adjustment guidelines. Dose adjustments have been recommended by two clinical groups based upon renal function, but they differ substantially (see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     \"Ifosfamide: Drug information\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    Kintzel suggests the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Creatinine clearance 46-60",
"      <span class=\"nowrap\">",
"       mL/minute:",
"      </span>",
"      Administer 80 percent of dose",
"     </li>",
"     <li>",
"      Creatinine clearance 31-45",
"      <span class=\"nowrap\">",
"       mL/minute:",
"      </span>",
"      Administer 75 percent of dose",
"     </li>",
"     <li>",
"      Creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/minute:",
"      </span>",
"      Administer 70 percent of dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, Aronoff suggests reducing the dose by 25 percent only in patients with creatinine clearance &lt;10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nitrosoureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;A slowly progressive, chronic interstitial nephritis that is generally irreversible can be induced by prolonged therapy with the nitrosoureas BCNU (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ), CCNU (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    ), methyl-CCNU (semustine), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Although the exact mechanism of nephrotoxicity is not completely elucidated, these agents may produce nephrotoxicity by alkylation of tubular cell proteins. Their metabolites, which are thought to be responsible for nephrotoxicity, persist in the urine for up to 72 hours following administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrotoxicity has been most common with high doses (&gt;1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    of methyl-CCNU (semustine, which is no longer available in any country), with renal dysfunction typically progressing to renal failure within three to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. In one report, histologic changes in the kidney included glomerular sclerosis without immune deposits and interstitial fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/51\">",
"     51",
"    </a>",
"    ]. In contrast, nephrotoxicity was reported in less than 20 percent of patients with malignant melanoma treated with low dose methyl-CCNU in the adjuvant setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the primary dose limiting toxicity of BCNU is pulmonary injury, it has been associated with renal insufficiency in several reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/56\">",
"     56",
"    </a>",
"    ]. Histologic changes include mild interstitial infiltrates and tubular changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     Streptozocin",
"    </a>",
"    , a nonmyelosuppressive nitrosourea, has been associated with nephrotoxicity in up to 75 percent of patients treated for prolonged periods of time. Although nephrotoxicity is not necessarily dose-related, it is rare in patients treated with &lt;1 to 1.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/57\">",
"     57",
"    </a>",
"    ]. Streptozocin damages the renal tubules, causing atrophy and tubulointerstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/58\">",
"     58",
"    </a>",
"    ]; one case report also describes uric acid nephrolithiasis and acute renal failure following streptozocin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/59\">",
"     59",
"    </a>",
"    ] and another diabetes insipidus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild proteinuria or an asymptomatic elevation in the plasma creatinine concentration is usually the first sign of renal involvement, followed by signs of proximal tubular damage (eg, phosphaturia, glycosuria, aminoaciduria, uricosuria and bicarbonaturia). In one study of 52 patients treated for advanced islet cell carcinoma, the most common sign of nephrotoxicity was proteinuria (51 percent), followed by renal tubular acidosis (17 percent), Fanconi syndrome (13 syndrome), and azotemia (26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/61\">",
"     61",
"    </a>",
"    ]. Nephrotoxicity contributed to death in 11 percent of treated patients.",
"   </p>",
"   <p>",
"    The onset of clinical nephrotoxicity may be delayed from several months to as long as several years after nitrosoureas have been discontinued. As a result, careful long-term follow-up is essential. If it develops, nephrotoxicity typically persists for approximately two to three weeks after the drug is stopped. There is no known therapy for this disorder once it has begun. It has been suggested, however, that the nephrotoxicity can be diminished by the use of forced diuresis (2 liters of isotonic saline per hour for two hours) when the drug is being given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little published information is available to guide dosing of nitrosoureas in patients with renal impairment. The US FDA-approved labeling does not contain dosing adjustments. Aronoff recommends the following modification scheme for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     \"Streptozocin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     \"Lomustine: Drug information\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Creatinine clearance 10 to 50",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Administer 75 percent of dose",
"     </li>",
"     <li>",
"      Creatinine clearance &lt;10",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Administer 25 to 50 percent of dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    is an orally active alkylating agent with efficacy in brain tumors. Patients with mild to moderate renal dysfunction have similar pharmacokinetics compared to those with normal function, although patients with severe renal dysfunction have not been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Melphalan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     Melphalan",
"    </a>",
"    is an orally active alkylating agent that is used mainly for the treatment of multiple myeloma. Melphalan has been associated with the development of SIADH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the drug is mostly metabolized by the liver, 10 to 30 percent is excreted unchanged in the urine. The FDA-approved labeling for IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    suggests a 50 percent dose reduction in patients with renal insufficiency (defined only as a BUN &ge;30",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    Others recommend that the dose of IV melphalan used as a conditioning regimen for hematopoietic cell transplantation be reduced from 200 to 140",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in patients with serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aronoff recommends the following dose modification for oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     \"Melphalan: Drug information\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Creatinine clearance 10 to 50",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Administer 75 percent of dose",
"     </li>",
"     <li>",
"      Creatinine clearance &lt;10",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Administer 50 percent of dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians recommend a 25 percent dose reduction in oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    for patients with multiple myeloma and a serum creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    to prevent severe myelotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antitumor antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mitomycin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common form of nephrotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    is a syndrome of renal failure and microangiopathic hemolytic anemia termed \"thrombotic thrombocytopenic",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome\" (TTP-HUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. It is most likely to occur after at least six months of therapy, and the overall incidence is related to cumulative dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. As an example, in one series, renal complications from mitomycin developed in 2, 11, and 28 percent of patients receiving cumulative doses of 50, 50 to 69, and &gt;70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Chemotherapy agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is presumed that direct endothelial injury is the initiating event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/71,75\">",
"     71,75",
"    </a>",
"    ]. In experimental animals, direct infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    in the renal artery of anesthetized rats produces a classic microangiopathic lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/75\">",
"     75",
"    </a>",
"    ]. However, the onset of clinically evident disease is often delayed in humans, frequently occurring months after chemotherapy has been discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients typically present with slowly progressive renal failure, hypertension, and a relatively bland urine sediment, often occurring in the absence of clinically apparent tumor. Renal failure is often reversible with plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/76,77\">",
"     76,77",
"    </a>",
"    ] or immunoabsorption of serum on a staphylococcal protein A column [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28179?source=see_link\">",
"     \"Plasmapheresis with hemodialysis equipment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    can be administered to patients with renal insufficiency, with close monitoring for signs and symptoms of",
"    <span class=\"nowrap\">",
"     TTP/HUS.",
"    </span>",
"    The FDA-approved labeling states to avoid use in patients with serum creatine &gt;1.7",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    but offers no other dosage adjustment guidelines. Others note that urinary elimination accounts for only 20 percent of an administered dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6\">",
"     6",
"    </a>",
"    ] and recommend dose reduction of 25 percent only for patients with creatinine clearance &lt;10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     \"Mitomycin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bleomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal toxicity is not described as a complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    therapy. However, renal insufficiency is known to alter bleomycin elimination, particularly in patients with a creatinine clearance below 25 to 35",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    increasing the likelihood of treatment-related toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few patients with renal impairment receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    have been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/47,82\">",
"     47,82",
"    </a>",
"    ]. The US FDA approved manufacturer's product information specifies a dose reduction schema for patients with a creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Aronoff suggests a 25 percent dose reduction for patients with creatinine clearance 10 to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a 50 percent reduction for clearance &lt;10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     \"Bleomycin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638201252\">",
"    <span class=\"h3\">",
"     Anthracyclines and related agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     Epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , as well as their major metabolites, are excreted mainly through the bile, and to a lesser extent, by urinary excretion. Although Aronoff recommends no dose reduction for epirubicin or any other anthracycline in patients with renal failure for any of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ], the FDA-approved labeling recommends epirubicin dose adjustment in patients with severe renal impairment (serum creatinine &gt;5",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    A 50 percent dose reduction is also recommended for daunorubicin in patients with serum creatinine &gt;3",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antimetabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elimination of many of these drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    , is at least partially dependent upon kidney function. Of the clinically useful antimetabolites, only methotrexate is associated with significant renal toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to 5-fluorouracil, which is cleared through nonrenal mechanisms and therefore does not require dose adjustment in patients with renal dysfunction, the oral fluoropyrimidine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is contraindicated in patients with severe renal impairment (creatinine clearance below 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and the initial dose should be reduced by 25 percent in patients with clearances values 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     \"Capecitabine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935841151\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is excreted renally. The initial dose should be reduced in patients with renal impairment. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     \"Hydroxyurea: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    at doses less than 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is usually not associated with renal toxicity, unless underlying renal dysfunction is present. In contrast, high-dose intravenous methotrexate (1 to 15",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    can precipitate in the tubules and induce tubular injury; at particular risk are patients who are volume depleted and those who excrete an acidic urine. Maintenance of adequate urinary output and alkalinization will lessen the probability of methotrexate precipitation. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link&amp;anchor=H13#H13\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Renal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=see_link&amp;anchor=H4164341#H4164341\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    can also produce a transient decrease in GFR, with complete recovery within six to eight hours of discontinuing the drug. The mechanism responsible for this functional renal impairment involves afferent arteriolar constriction or mesangial cell constriction that produces reduced glomerular capillary surface area, diminished glomerular capillary perfusion and pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/83\">",
"     83",
"    </a>",
"    ]. Methotrexate has also been associated with SIADH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    excretion is decreased in patients who have renal insufficiency, and more significant bone marrow and gastrointestinal toxicity may result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/84\">",
"     84",
"    </a>",
"    ]. Patients with ileal conduits and those with third space fluid collections (eg, ascites, pleural effusion) may experience greater methotrexate toxicity, particularly if their creatinine clearance is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA-approved labeling does not contain dosage adjustment guidelines. However, dose modification guidelines have been proposed by several clinical groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     \"Methotrexate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    , a derivative of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    that is approved for treatment of advanced non-small cell lung cancer and pleural mesothelioma, is rarely associated with renal damage (including acute tubular necrosis, renal tubular acidosis, and diabetes insipidus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    is primarily excreted unchanged by renal excretion. Dosage adjustment is not necessary in patients with a creatinine clearance &ge;45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/88\">",
"     88",
"    </a>",
"    ]; however, the manufacturer recommends the drug not be used in patients with a creatinine clearance &lt;45",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Furthermore, there are recommendations for avoidance of NSAIDs in the days prior to and immediately following each dose of pemetrexed in patients with mild to moderate renal dysfunction (CrCl 45 to 79",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    because of the potential for decreased clearance of pemetrexed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     \"Pemetrexed: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pentostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA-approved labeling does not contain dosing adjustment guidelines for patients with renal insufficiency. However, some clinicians suggest dose reduction for patients with a creatinine clearance &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,89\">",
"     6,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fludarabine and cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of each administered dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    is excreted in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/90\">",
"     90",
"    </a>",
"    ]. Specific dose adjustment guidelines are available from the US FDA which differ from those suggested in Canada and those suggested by Aronoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     \"Fludarabine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no available data on which to base a recommendation for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , and US FDA dose adjustment guidelines are not available. Aronoff recommends 25 and 50 percent dose reductions for patients with creatinine clearance 10 to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and &lt;10",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is a cell cycle-specific pyrimidine antagonist that has been associated with renal failure and microangiopathic hemolytic anemia (thrombotic thrombocytopenic",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. &nbsp;Prior therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C may be a risk factor for the development of hemolytic uremic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/92\">",
"     92",
"    </a>",
"    ]. Drug discontinuation is recommended if this occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Chemotherapy agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with elevated creatinine levels may have greater than expected toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , even at reduced doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/93\">",
"     93",
"    </a>",
"    ], a dose modification scheme based upon renal dysfunction has not been developed. The US Food and Drug Administration-approved labeling states only that gemcitabine should be administered with caution in patients with evidence of significant renal dysfunction.",
"   </p>",
"   <p>",
"    Retrospective reports suggest that administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is feasible in patients with chronic renal failure on hemodialysis. In these cases, hemodialysis was initiated within 24 hours after each dose of gemcitabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/94\">",
"     94",
"    </a>",
"    ]. Patients receiving long term hemodialysis may be at higher risk of developing significant gemcitabine-related hematological toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA-approved labeling does not contain renal dosing adjustment guidelines. However, guidelines have been suggested by some clinicians for patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (&gt;2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,7,95\">",
"     6,7,95",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     \"Cytarabine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Vinca alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    are associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a small number of treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although dose reduction is not needed for patients with renal insufficiency, dose reduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    is suggested by some authors in patients with ESRD undergoing hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Topotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     Topotecan",
"    </a>",
"    , an inhibitor of topoisomerase I, is not associated with renal toxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     Topotecan",
"    </a>",
"    is predominantly cleared by the kidneys, and increased toxicity may be seen in patients with moderate renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7,98\">",
"     7,98",
"    </a>",
"    ]. The FDA-approved labeling recommends specific dosage adjustment for patients with a creatinine clearance &lt;40",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Slightly different guidelines have been suggested by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary excretion accounts for approximately 20 to 40 percent of each administered dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . The US FDA-approved labeling recommends specific dosage adjustments for renal insufficiency if the creatinine clearance is &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Slightly different guidelines have been suggested by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The taxanes undergo minimal renal excretion. The limited data indicate that both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    can be safely administered to patients with renal insufficiency and that dose modification is not required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/7\">",
"     7",
"    </a>",
"    ]. Both paclitaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/99-101\">",
"     99-101",
"    </a>",
"    ] and docetaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/102\">",
"     102",
"    </a>",
"    ] have been administered safely to patients on chronic hemodialysis, although some guidelines suggest a dose reduction for docetaxel in patients undergoing hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     Cabazitaxel",
"    </a>",
"    is a new semisynthetic taxane. Cases of renal failure were reported in a randomized trial conducted in men with metastatic prostate cancer, including four cases with a fatal outcome. Most occurred in association with sepsis, dehydration, or obstructive uropathy. Hemorrhagic cystitis has also been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link&amp;anchor=H12#H12\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Second-line chemotherapy: cabazitaxel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystitis in patients with cancer\", section on 'Chemotherapy-induced cystitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no guidelines for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     cabazitaxel",
"    </a>",
"    dose reduction in patients with mild to moderate renal insufficiency. In population-based pharmacokinetic trials, there was no difference in clearance in patients with mild or moderate renal insufficiency (creatinine clearance &lt;80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    but &gt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/103\">",
"     103",
"    </a>",
"    ]. The US FDA approved drug labeling recommends that the drug be used with caution in those with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    doses require modification in patients with renal insufficiency. Whereas the kidneys are responsible for only a small fraction of drug clearance, and only small amounts of irinotecan have been recovered in urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/104\">",
"     104",
"    </a>",
"    ], several reports note excess toxicity in patients with end stage renal disease (ESRD), even with reduced doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. This has been attributed to excess exposure to the metabolite SN-38 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H40#H40\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no formal guidelines for dose reduction in the setting of renal disease, and the FDA-approved labeling does not contain dosing adjustment guidelines for patients with renal insufficiency. However, a review of published case reports of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    use in patients with ESRD suggests that weekly doses of 50 to 80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    were generally tolerated whereas even single doses of &gt;125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    were associated with severe adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA-approved labeling states that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is not recommended for use in patients on dialysis; however, some authors suggest dose reduction for patients with ESRD undergoing hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is an analog of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , which has clinical utility in the treatment of multiple myeloma and myelodysplastic syndrome (MDS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H2443602#H2443602\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Patients with 5q deletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with multiple myeloma frequently have renal impairment. The half life and area under the concentration x time curve (AUC) for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    increase as creatinine clearance decreases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/109\">",
"     109",
"    </a>",
"    ]. As a result, patients with preexisting renal insufficiency are at risk for increased drug toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. In an analysis of 72 patients given",
"    <span class=\"nowrap\">",
"     lenalidomide/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"      dexamethasone",
"     </a>",
"    </span>",
"    for first line treatment of multiple myeloma, patients with a creatinine clearance (ClCr) &lt;40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    had an 8.4-fold increased likelihood of requiring a lenalidomide dose reduction for grade 3 or worse myelosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/110\">",
"     110",
"    </a>",
"    ]. The FDA-approved labeling for lenalidomide contains renal dosing adjustment guidelines.",
"   </p>",
"   <p>",
"    Rare cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -induced renal failure have been reported, including a case of biopsy-proven acute interstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2965306\">",
"    <span class=\"h2\">",
"     Eribulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"     Eribulin",
"    </a>",
"    mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. Formal pharmacokinetic trials have not been conducted in patients with renal impairment. The only available data suggest that patients with moderate or severe renal impairment can tolerate doses of 1.4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    without unexpected toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/114\">",
"     114",
"    </a>",
"    ]. However, the FDA-approved labeling guidelines recommend a lower starting dose in patients with moderate renal insufficiency (creatinine clearance 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"     \"Eribulin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627315883\">",
"    <span class=\"h2\">",
"     Arsenic trioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug exposure may be higher in patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/115\">",
"     115",
"    </a>",
"    ]. While no specific recommendations for dose adjustment in patients with renal failure are available in the FDA-approved labeling, these patients should be closely monitored for toxicity during treatment, and a dose reduction may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     TARGETED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several molecularly-targeted agents are associated with nephrotoxicity (",
"    <a class=\"graphic graphic_table graphicRef56245 \" href=\"mobipreview.htm?1/42/1708\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     VEGF pathway inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different approaches have been used to block the vascular endothelial growth factor (VEGF) pathway: VEGF ligand inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    ), which bind to and inhibit ligand binding to the VEGF receptor (VEGFR), thus preventing activation of the receptor, and antiangiogenic small molecule tyrosine kinase inhibitors (TKIs) (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    ), which block the intracellular domain of the VEGFR.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , and the small molecule antiangiogenic TKIs produce asymptomatic albuminuria, occasionally causing the nephrotic syndrome. Hypertension frequently accompanies proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651225341#H1651225341\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Proteinuria/nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although proteinuria appears to be an effect common to all agents targeted at the VEGF pathway, the factors associated with the occurrence and severity of proteinuria are unknown. Preexisting renal disease (including higher baseline urine protein levels and hypertension) and renal cell carcinoma as compared to other malignant diseases may be predisposing factors.",
"   </p>",
"   <p>",
"    The FDA-approved manufacturer's labeling for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    recommends intermittent monitoring for the development of proteinuria but does not provide specific recommendations, except temporary withholding of the drug if protein excretion if &gt;2",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours, and permanent discontinuation for the nephrotic syndrome. However, this complication is uncommon and many institutions do not routinely dipstick urine prior to each dose of bevacizumab. Baseline and periodic urinalysis is also recommended during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    , with treatment interruption or discontinuation for patients who develop moderate to severe proteinuria (defined as &ge;3",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours for pazopanib but undefined for axitinib). There are no guidelines for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    ; however, good clinical practice dictates baseline and periodic assessment of proteinuria for these agents also. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651225348#H1651225348\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Management'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1039596285\">",
"    <span class=\"h3\">",
"     Dosing in patients with renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small molecule TK inhibitors are partly excreted by the kidneys. These drugs can be safely given to patients with renal insufficiency, with adequate monitoring and dose adjustment, as needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. However, at least one report suggests that more than one-half of patients who have renal insufficiency at the start of therapy will experience a further rise in creatinine during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1039596292\">",
"    <span class=\"h4\">",
"     Sorafenib and sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA-approved manufacturer&rsquo;s labeling for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    suggests no dose adjustment for patients with mild, moderate, or severe renal impairment not undergoing dialysis. However, a phase I study indicated that the initial dose of sorafenib should be reduced to 200 mg twice daily for patients with a creatinine clearance between 20 and 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and 200 mg once daily for those on hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/118\">",
"     118",
"    </a>",
"    ]. Conclusions regarding initial dose could not be reached in patients with a creatinine clearance less than 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    who were not undergoing hemodialysis.",
"   </p>",
"   <p>",
"    Higher doses (200 mg twice daily) have been associated with a higher incidence of adverse effects in patients undergoing hemodialysis in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/119\">",
"     119",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/120\">",
"     120",
"    </a>",
"    ]. Some patients may tolerate dose escalation to 400 mg twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetics and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    has been evaluated in a small number of patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/120,122-124\">",
"     120,122-124",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 24 patients, a single dose of 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      appeared to be well tolerated in those with severe renal impairment (creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       ml/min)",
"      </span>",
"      or end stage renal disease (ESRD) on hemodialysis. The pharmacokinetics of sunitinib and its major metabolite (SU12662) in patients with severe renal impairment appeared similar to that of patients with normal renal function, while in patients with ESRD, plasma exposure to both sunitinib and SU12662 was actually lower compared to patients with normal or severely impaired renal function not on dialysis.",
"     </li>",
"     <li>",
"      In a published case report of two patients with ESRD receiving repeated doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (daily for four weeks on, two weeks off) for renal cell cancer, the pharmacokinetics of sunitinib were similar to those of patients with normal renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report included 19 patients with an estimated GFR &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at the start of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      therapy for advanced renal cell cancer, 10 of whom were undergoing dialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/124\">",
"       124",
"      </a>",
"      ]. Starting doses were from 25 to 50 mg daily for four of every six weeks. Treatment efficacy was comparable to that reported in patients with normal renal function. Dose reduction for toxicity was required in eight, but only one patient required treatment discontinuation. Similar results have been reported by others in patients with renal cell cancer undergoing hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, these data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    doses of 25 to 50 mg daily are well tolerated in patients with severe renal dysfunction or ESRD on hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540819\">",
"    <span class=\"h4\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is an orally active inhibitor of several tyrosine kinases including RET, VEGFR and EGFR. It is partially excreted in urine, and the manufacturer&rsquo;s labeling recommends a dose reduction from 300 to 200 mg daily for patients with moderate to severe renal insufficiency (creatinine clearance &le; 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     EGFR pathway inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    are small molecule inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), which are used in the treatment of non-small cell lung cancer. Although data are limited, dose modification is not required in patients with impaired renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monoclonal antibodies targeting the epidermal growth factor receptor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , matuzumab) are associated with the progressive development of hypomagnesemia due to renal magnesium wasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. The frequency of this complication was illustrated in a meta-analysis of 19 clinical reports totaling 3081 patients assigned to cetuximab-based treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/131\">",
"     131",
"    </a>",
"    ]. Thirty-seven percent of patients developed hypomagnesemia of any grade during therapy; the incidence of grade 3 or 4 hypomagnesemia (&lt;0.9",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    was 5.6 percent. Hypomagnesemia resolves after treatment is discontinued. Hypomagnesemia may lead to secondary hypocalcemia. Periodic monitoring of serum magnesium and calcium levels is warranted during therapy and for eight weeks after treatment discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    also causes hypokalemia in approximately 8 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/132\">",
"     132",
"    </a>",
"    ]. The exact mechanism underlying this complication is not established although a direct nephrotoxic effect has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/133\">",
"     133",
"    </a>",
"    ]; magnesium deficiency may also contribute. Thus, periodic monitoring of serum potassium is warranted during therapy with cetuximab. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link\">",
"     \"Causes of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is a small molecule tyrosine kinase inhibitor that targets c-kit, a key molecular abnormality in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute and chronic kidney injury have been rarely described in patients treated with extended duration",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/134-136\">",
"     134-136",
"    </a>",
"    ]; in one report, the mean decrease per year was 2.77",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/134\">",
"     134",
"    </a>",
"    ]. Leukemic infiltration into the kidney should always be considered when a patient with CML presents with renal impairment, regardless of the clinical stage, as the renal failure may respond to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a single case report of SIADH from high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the literature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US FDA-approved manufacturer&rsquo;s labeling recommends modification of the initial dose for patients with mild to moderate renal dysfunction (CrCl &lt;39",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    because of reduced drug clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/138\">",
"     138",
"    </a>",
"    ]. Owing to the lack of data, patients with severe dysfunction (creatinine clearance &lt;20",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    should be approached cautiously; limited data suggest a dose of 100 mg daily is tolerated in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/138\">",
"     138",
"    </a>",
"    ] .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    can be safely administered to patients on hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/139,140\">",
"     139,140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a monoclonal antibody directed against CD20 that is active in the treatment of lymphoid malignancies. Rituximab has been associated with electrolyte imbalance and acute renal failure in patients with high circulating tumor cells",
"    <span class=\"nowrap\">",
"     (&gt;25,000/mm3)",
"    </span>",
"    or a high tumor burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. This generally occurs within 12 to 24 hours of the first dose and is presumably the result of tumor lysis syndrome. Prophylaxis should be considered for patients at high risk. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no formal published guidelines, but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    should probably be discontinued in patients who develop a rising creatinine or oliguria during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Temsirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    is a parenterally administered rapamycin analog that functions as a competitive inhibitor of the mammalian target of rapamycin (mTOR) kinase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    is cleared mainly by the liver with some excretion in the feces. Due to the small amount of renal excretion (less than 5 percent), dose adjustment is not needed in the setting of renal insufficiency or hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/143\">",
"     143",
"    </a>",
"    ]. However, one study did note a higher rate of treatment-related rash (45 versus 15 percent) and infection (27 versus 8 percent) in patients receiving mTOR inhibitors for renal cell cancer who had renal insufficiency (creatinine clearance &le;60",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    compared to those with normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     OTHER BIOLOGIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/33/30231?source=see_link\">",
"     Recombinant human interleukin-2",
"    </a>",
"    (IL-2) can induce a relatively severe capillary leak syndrome, leading to edema, plasma volume depletion, and a reversible fall in glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. For example, in one study of 199 consecutive patients, most patients experienced oliguria, hypotension, and weight gain, and 13 percent of cycles were discontinued because of a substantial rise in the plasma creatinine concentration (from 1.2 to 2.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [106 to 238",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/146\">",
"     146",
"    </a>",
"    ]. Poor renal function promptly reversed after cessation of therapy.",
"   </p>",
"   <p>",
"    It has been proposed that plasma volume depletion is responsible for the development of acute renal failure. Although the clinical course and improvement in creatinine clearance and urine output following low-dose dopamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/147\">",
"     147",
"    </a>",
"    ] are compatible with this hypothesis, the observations that renal plasma flow is normal in affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/144\">",
"     144",
"    </a>",
"    ] and that the urinalysis may reveal red cells, white cells, granular casts, and modest proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/145\">",
"     145",
"    </a>",
"    ] suggest that there may also be some direct renal injury.",
"   </p>",
"   <p>",
"    Patients with normal renal function before treatment usually recover within the first week after discontinuing therapy. Patients with underlying renal dysfunction may take longer periods of time to recover from the renal failure.",
"   </p>",
"   <p>",
"    Therapy for renal failure secondary to IL-2 treatment is supportive. It is directed at maintaining intravascular volume and stabilizing hemodynamic parameters, as well as avoiding other potential nephrotoxic agents. Preventive measures include a strict selection of patients who are candidates for IL-2 therapy. Older patients, patients with underlying renal failure, and patients taking nephrotoxic agents are at higher risk for complications such as capillary leak syndrome and prerenal azotemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant interferon alpha (IFN-a) can cause proteinuria, which can be massive; the histology is consistent with minimal change nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/148\">",
"     148",
"    </a>",
"    ]. Thrombotic microangiopathy is a rare complication, seen mostly in patients with chronic myeloid leukemia treated with high doses of IFN-a over long periods of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon gamma has been associated with acute tubular necrosis when used for the treatment of acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/48/41738/abstract/150\">",
"     150",
"    </a>",
"    ]. However, this agent is not currently used clinically for treatment of any neoplastic condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy and biologic antitumor agents can cause nephrotoxicity by a variety of different mechanisms (",
"      <a class=\"graphic graphic_table graphicRef54722 \" href=\"mobipreview.htm?28/4/28749\">",
"       table 2",
"      </a>",
"      ). Several factors can potentiate renal dysfunction and contribute to the nephrotoxic potential of antineoplastic drugs. These include intravascular volume depletion, the concomitant use of non-chemotherapeutic nephrotoxic drugs (eg, aminoglycoside antibiotics, nonsteroidal antiinflammatory drugs) or radiographic ionic contrast media in patients with or without preexisting renal dysfunction, tumor-related urinary tract obstruction, and intrinsic renal disease that is idiopathic, related to other comorbidities, or to the cancer itself. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for nephrotoxicity'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These factors should be considered by the treating oncologist before initiating treatment, in order to minimize the risk of excessive toxicity. &nbsp;",
"     </li>",
"     <li>",
"      For those drugs in which renal excretion is an important determinant of elimination of the intact drug or an active metabolite, renal impairment can alter excretion, and increase systemic toxicity. Dose adjustment is often required. Measurement of serum drug concentrations is not usually performed for patients treated with chemotherapeutic agents. Dose adjustment in this setting is typically based upon two factors: an estimation of glomerular filtration rate (GFR), which serves as an index of the number of functioning nephrons, and evaluation of clinical signs of drug toxicity (eg, neutropenia, thrombocytopenia). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Estimation of GFR for possible dose adjustment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following issues are pertinent to dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , which is based upon GFR:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      dosing uses the Calvert formula, which is based upon desired exposure (area under the curve [AUC] of concentration X time) and the glomerular filtration rate (GFR). When the GFR is estimated based upon measured serum creatinine, we suggest limiting the maximal GFR to 125",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      for this calculation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion does not apply if the GFR is directly measured. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'AUC dose calculation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When calculating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      doses, actual weight should be used for estimation of the GFR by the Cockcroft-Gault equation as long as patients have a body mass index of &lt;25 (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). For other patients, use of an adjusted weight is suggested (adjusted weight (kg) = ((actual weight - ideal weight) x 0.40) + ideal weight). A calculator for ideal body weight is available (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=see_link\">",
"       calculator 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most commonly used chemotherapeutic agents for which dose modification may be needed in the setting of renal insufficiency are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef56245 \" href=\"mobipreview.htm?1/42/1708\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cytotoxic drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'VEGF pathway inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/1\">",
"      Boesler B, Czock D, Keller F, et al. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 2005; 20:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/2\">",
"      Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/3\">",
"      Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/4\">",
"      Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/5\">",
"      Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006; 24:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/6\">",
"      Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995; 21:33.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff GM, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th, American College of Physicians, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/8\">",
"      Tomita M, Kurata H, Aoki Y, et al. Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 2001; 12:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/9\">",
"      Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003; 88:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/10\">",
"      Ribrag V, Droz JP, Morizet J, et al. Test dose-guided administration of cisplatin in an anephric patient: a case report. Ann Oncol 1993; 4:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/11\">",
"      Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/12\">",
"      McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med 1991; 90:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/13\">",
"      Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Williston Park) 1991; 5:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/14\">",
"      Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994; 73:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/15\">",
"      Tscherning C, Rubie H, Chancholle A, et al. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994; 73:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/16\">",
"      Welborn J, Meyers FJ, O'Grady LF. Renal salt wasting and carboplatinum. Ann Intern Med 1988; 108:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/17\">",
"      English MW, Lowis SP, Peng B, et al. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. Br J Cancer 1996; 73:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/18\">",
"      Chatelut E, Rostaing L, Gualano V, et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 1994; 66:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/19\">",
"      Motzer RJ, Niedzwiecki D, Isaacs M, et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol 1990; 27:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/20\">",
"      Yanagawa H, Takishita Y, Bando H, et al. Carboplatin-based chemotherapy in patients undergoing hemodialysis. Anticancer Res 1996; 16:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/21\">",
"      Inoue A, Saijo Y, Kikuchi T, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/22\">",
"      Veal GJ, English MW, Grundy RG, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol 2004; 54:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/23\">",
"      Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/24\">",
"      Nagao S, Fujiwara K, Imafuku N, et al. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula. Gynecol Oncol 2005; 99:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/25\">",
"      Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann Intern Med 1973; 79:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/26\">",
"      Dubs A, Taverna C. In reply. J Clin Oncol 2005; 23:3650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/27\">",
"      Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/28\">",
"      Ekhart C, de Jonge ME, Huitema AD, et al. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006; 12:6502.",
"     </a>",
"    </li>",
"    <li>",
"     file://nkdep.nih.gov/labprofessionals/Clinical_Laboratories.htm (Accessed on August 18, 2011).",
"    </li>",
"    <li>",
"     FDA safety alert available online at file://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm228974.htm (Accessed on October 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/31\">",
"      De Jonge ME, Math&ocirc;t RA, Van Dam SM, et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 2002; 50:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/32\">",
"      Ekhart C, Rodenhuis S, Schellens JH, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 2009; 64:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/33\">",
"      Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI&gt;or=27 or cachexia. Cancer Chemother Pharmacol 2006; 57:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/34\">",
"      L&eacute;vi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/35\">",
"      Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol 2002; 13:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/36\">",
"      Labaye J, Sarret D, Duvic C, et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant 2005; 20:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/37\">",
"      Ulusakarya A, Misra S, Haydar M, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 2010; 27:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/38\">",
"      Chollet P, Bensma&iuml;ne MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/39\">",
"      Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/40\">",
"      Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 2011; 68:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/41\">",
"      Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010; 66:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/42\">",
"      DeFronzo RA, Colvin OM, Braine H, et al. Proceedings: Cyclophosphamide and the kidney. Cancer 1974; 33:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/43\">",
"      Bode U, Seif SM, Levine AS. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med Pediatr Oncol 1980; 8:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/44\">",
"      Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/45\">",
"      Bramwell V, Calvert RT, Edwards G, et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979; 3:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/46\">",
"      Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/47\">",
"      Jank�� I, Modr Z, Krebs V. A set of simple aids to drug dosage adjustment in renal insufficiency. Int J Clin Pharmacol Ther Toxicol 1990; 28:27.",
"     </a>",
"    </li>",
"    <li>",
"     Cancer Drug information from Cancer Care Ontario file://cancercare.on.ca/cms/one.aspx?portalId=1377&amp;pageId=10760 (Accessed on February 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/49\">",
"      Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant 1999; 23:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/50\">",
"      Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data. Eur J Cancer 2012; 48:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/51\">",
"      Harmon WE, Cohen HJ, Schneeberger EE, Grupe WE. Chronic renal failure in children treated with methyl CCNU. N Engl J Med 1979; 300:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/52\">",
"      Narins RG, Carley M, Bloom EJ, Harrison DS. The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 1990; 10:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/53\">",
"      Sponzo RW, DeVita VT, Oliverio VT. Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man. Cancer 1973; 31:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/54\">",
"      Weiss RB, Posada JG Jr, Kramer RA, Boyd MR. Nephrotoxicity of semustine. Cancer Treat Rep 1983; 67:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/55\">",
"      Micetich KC, Jensen-Akula M, Mandard JC, Fisher RI. Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. Am J Med 1981; 71:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/56\">",
"      Schacht RG, Feiner HD, Gallo GR, et al. Nephrotoxicity of nitrosoureas. Cancer 1981; 48:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/57\">",
"      Sadoff L. Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother Rep 1970; 54:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/58\">",
"      Myerowitz RL, Sartiano GP, Cavallo T. Nephrotoxic and cytoproliferative effects of streptozotocin: report of a patient with multiple hormone-secreting islet cell carcinoma. Cancer 1976; 38:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/59\">",
"      Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/60\">",
"      Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987; 9:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/61\">",
"      Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/62\">",
"      Tobin MV, Warenius HM, Morris AI. Forced diuresis to reduce nephrotoxicity of streptozotocin in the treatment of advanced metastatic insulinoma. Br Med J (Clin Res Ed) 1987; 294:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/63\">",
"      Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/64\">",
"      Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, et al. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. Cancer 1985; 55:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/65\">",
"      Helson L, Sadof MD, Wernovsky G, Gulati S. L-phenylalanine mustard-dianhydrogalactitol and hyponatremia. Pediatr Hematol Oncol 1986; 3:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/66\">",
"      Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/67\">",
"      Carlson K, Hjorth M, Knudsen LM, Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005; 128:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/68\">",
"      Price TM, Murgo AJ, Keveney JJ, et al. Renal failure and hemolytic anemia associated with mitomycin C. A case report. Cancer 1985; 55:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/69\">",
"      Poch E, Gonz&aacute;lez-Clemente JM, Torras A, et al. Silent renal microangiography after mitomycin C therapy. Am J Nephrol 1990; 10:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/70\">",
"      Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985; 3:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/71\">",
"      Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/72\">",
"      Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/73\">",
"      Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/74\">",
"      Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/75\">",
"      Cattell V. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Am J Pathol 1985; 121:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/76\">",
"      Garibotto G, Acquarone N, Saffioti S, et al. Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis. Nephron 1989; 51:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/77\">",
"      Poch E, Almirall J, Nicolas JM, et al. Treatment of mitomycin-C-associated hemolytic uremic syndrome with plasmapheresis. Nephron 1990; 55:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/78\">",
"      Snyder HW Jr, Mittelman A, Oral A, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993; 71:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/79\">",
"      Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/80\">",
"      Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980; 64:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/81\">",
"      McLeod BF, Lawrence HJ, Smith DW, et al. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 1987; 60:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/82\">",
"      Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology (Williston Park) 1992; 6:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/83\">",
"      Howell SB, Carmody J. Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 1977; 61:1389.",
"     </a>",
"    </li>",
"    <li>",
"     Schilsky RL. Renal and metabolic toxicities of cancer treatment. In: Toxicity of chemotherapy, Perry MC, Yarbro JW (Eds), Grune &amp; Stratton, Philadelphi 1984. p.317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/85\">",
"      Bowyer GW, Davies TW. Methotrexate toxicity associated with an ileal conduit. Br J Urol 1987; 60:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/86\">",
"      Stavroulopoulos A, Nakopoulou L, Xydakis AM, et al. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 2010; 32:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/87\">",
"      Vootukuru V, Liew YP, Nally JV Jr. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 2006; 23:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/88\">",
"      Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006; 24:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/89\">",
"      Lathia C, Fleming GF, Meyer M, et al. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol 2002; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/90\">",
"      Lichtman SM, Etcubanas E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest 2002; 20:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/91\">",
"      Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/92\">",
"      Glezerman I, Kris MG, Miller V, et al. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 2009; 71:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/93\">",
"      Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780.",
"     </a>",
"    </li>",
"    <li>",
"     Matsuda M. Gemcitabine for patients with chronic renal failure on hemodialysis (abstract #15189). J Clin Oncol 2007; 25:15189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/95\">",
"      Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/96\">",
"      Cutting HO. Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy. Am J Med 1971; 51:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/97\">",
"      Garrett CA, Simpson TA Jr. Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Ann Pharmacother 1998; 32:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/98\">",
"      O'Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14:3062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/99\">",
"      Furuya Y, Takihana Y, Araki I, et al. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report]. Gan To Kagaku Ryoho 2003; 30:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/100\">",
"      Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 2002; 84:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/101\">",
"      Baur M, Fazeny-Doerner B, Olsen SJ, Dittrich C. High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. Int J Gynecol Cancer 2008; 18:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/102\">",
"      Mencoboni M, Olivieri R, Vannozzi MO, et al. Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Chemotherapy 2006; 52:147.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA labeling information for cabazitaxel available at file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19208 (Accessed on July 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/104\">",
"      Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/105\">",
"      V&eacute;nat-Bouvet L, Saint-Marcoux F, Lagarde C, et al. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. Anticancer Drugs 2007; 18:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/106\">",
"      Shinozaki E, Mizunuma N, Tanabe M, et al. [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer]. Gan To Kagaku Ryoho 2005; 32:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/107\">",
"      Ashizawa T, Iwahori T, Yokoyama T, et al. Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer. Acta Med Okayama 2010; 64:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/108\">",
"      Czock D, Rasche FM, Boesler B, et al. Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 2009; 43:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/109\">",
"      Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/110\">",
"      Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na&iuml;ve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/111\">",
"      Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116:3807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/112\">",
"      Lipson EJ, Huff CA, Holanda DG, et al. Lenalidomide-induced acute interstitial nephritis. Oncologist 2010; 15:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/113\">",
"      Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008; 49:1108.",
"     </a>",
"    </li>",
"    <li>",
"     Synold, TW, Tsao-Wei, DD, Quinn, DI, et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial (abstract 2527). J clin Oncol 2010; 28:210s. Abstract available online at file://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=49636 (Accessed on February 07, 2011).",
"    </li>",
"    <li>",
"     Prescribing information for Arsenic trioxide available online at  file://www.trisenox.com/pdf/TRISENOX_pi.pdf (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/116\">",
"      Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010; 21:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/117\">",
"      Gupta S, Parsa V, Heilbrun LK, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 2011; 22:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/118\">",
"      Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/119\">",
"      Kennoki T, Kondo T, Kimata N, et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 2011; 41:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/120\">",
"      Masini C, Sabbatini R, Porta C, et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 2012; 110:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/121\">",
"      Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008; 74:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/122\">",
"      Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/123\">",
"      Izzedine H, Etienne-Grimaldi MC, Ren&eacute;e N, et al. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009; 20:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/124\">",
"      Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011; 108:1279.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA drug approval summary for vandetanib in medullary thyroid cancer available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/126\">",
"      Rossi A, Maione P, Del Gaizo F, et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005; 47:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/127\">",
"      Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007; 25:3055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/128\">",
"      Togashi Y, Masago K, Fukudo M, et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 2010; 5:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/129\">",
"      Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/130\">",
"      Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/131\">",
"      Cao Y, Liao C, Tan A, et al. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 2010; 56:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/132\">",
"      Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 2010; 66:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/133\">",
"      Ben Salem C, Hmouda H, Bouraoui K. Drug-induced hypokalaemia. Curr Drug Saf 2009; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/134\">",
"      Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011; 22:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/135\">",
"      Gafter-Gvili A, Ram R, Gafter U, et al. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature. Leuk Res 2010; 34:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/136\">",
"      Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/137\">",
"      Yuzawa Y, Sato W, Masuda T, et al. Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia. Intern Med 2010; 49:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/138\">",
"      Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/139\">",
"      Pappas P, Karavasilis V, Briasoulis E, et al. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005; 56:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/140\">",
"      Ozdemir E, Koc Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol 2006; 81:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/141\">",
"      Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/142\">",
"      Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/143\">",
"      Lunardi G, Vannozzi MO, Armirotti A, et al. Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol 2008; 26:5652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/144\">",
"      Belldegrun A, Webb DE, Austin HA 3rd, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/145\">",
"      Mercatello A, Hadj-A&iuml;ssa A, N&eacute;grier S, et al. Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. Kidney Int 1991; 40:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/146\">",
"      Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994; 12:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/147\">",
"      Memoli B, De Nicola L, Libetta C, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995; 26:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/148\">",
"      Selby P, Kohn J, Raymond J, et al. Nephrotic syndrome during treatment with interferon. Br Med J (Clin Res Ed) 1985; 290:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/149\">",
"      Zuber J, Martinez F, Droz D, et al. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002; 81:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/48/41738/abstract/150\">",
"      Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319:1397.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2834 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41738=[""].join("\n");
var outline_f40_48_41738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTIMATION OF GFR FOR POSSIBLE DOSE ADJUSTMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR NEPHROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263265423\">",
"      DRUG HANDLING IN DIALYSIS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CYTOTOXIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Carboplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - AUC dose calculation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10242529\">",
"      - Bendamustine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nitrosoureas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Melphalan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antitumor antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mitomycin C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bleomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H638201252\">",
"      - Anthracyclines and related agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antimetabolites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935841151\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pentostatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fludarabine and cladribine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Vinca alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Topotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Etoposide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2965306\">",
"      Eribulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627315883\">",
"      Arsenic trioxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      TARGETED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      VEGF pathway inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1039596285\">",
"      - Dosing in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1039596292\">",
"      Sorafenib and sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3540819\">",
"      Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      EGFR pathway inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Temsirolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      OTHER BIOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/42/1708\" title=\"table 1\">",
"      Chemo dose adj renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/4/28749\" title=\"table 2\">",
"      Chemo associated nephrotoxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?2/41/2706?source=related_link\" title=\"calculator 3\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=related_link\">",
"      Bleomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=related_link\">",
"      Capecitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=related_link\">",
"      Cisplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=related_link\">",
"      Cytarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/16/27909?source=related_link\">",
"      Drug removal during continuous renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=related_link\">",
"      Eribulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=related_link\">",
"      Fludarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=related_link\">",
"      Hydroxyurea: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14806?source=related_link\">",
"      Ifosfamide nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=related_link\">",
"      Ifosfamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=related_link\">",
"      Lomustine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=related_link\">",
"      Melphalan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=related_link\">",
"      Methotrexate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=related_link\">",
"      Mitomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=related_link\">",
"      Overview of renal disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=related_link\">",
"      Oxaliplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=related_link\">",
"      Pemetrexed: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28179?source=related_link\">",
"      Plasmapheresis with hemodialysis equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=related_link\">",
"      Streptozocin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=related_link\">",
"      Systemic treatment for unresectable malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_48_41739="Rx warfarin associated ICH";
var content_f40_48_41739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reversing anticoagulation in warfarin-associated intracerebral hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Management option",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to anticoagulation reversal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and cautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinuing warfarin therapy",
"       </td>",
"       <td>",
"        5 to 14 days",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin K*",
"       </td>",
"       <td>",
"        6 to 24 hours to correct the INR",
"       </td>",
"       <td>",
"        Replacement of factors IX and X takes longer than 24 hours; risk of anaphylaxis with intravenous injection; warfarin resistance lasting up to 1 week may occur after large doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fresh frozen plasma",
"       </td>",
"       <td>",
"        3 to 6 hours for infusion, typically 12 to 32 hours for reversal",
"       </td>",
"       <td>",
"        Volume (2 to 4 L to normalize INR) can be prohibitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin complex concentrate",
"       </td>",
"       <td>",
"        15 minutes after 10-minute to 1-hour infusion",
"       </td>",
"       <td>",
"        Limited availability; cost; variable factor VII content based on manufacturer; potentially prothrombotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor VIIa concentrate",
"       </td>",
"       <td>",
"        15 minutes after bolus infusion",
"       </td>",
"       <td>",
"        Short half-life; cost; potentially prothrombotic; uncertain safety. Only replaces factor VII and not the other vitamin K-dependent factors.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     INR: international normalized ratio.",
"     <br/>",
"     * A total of 10 mg intravenously by slow infusion throughout 10 minutes.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intercerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc 2007; 82:82. Copyright &copy; 2007 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41739=[""].join("\n");
var outline_f40_48_41739=null;
var title_f40_48_41740="Treatment of newly diagnosed Ph positive ALL";
var content_f40_48_41740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the treatment for newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Induction therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A BCR-ABL tyrosine kinase inhibitor (TKI)",
"        <strong>",
"         plus",
"        </strong>",
"        one of the following combination chemotherapy regimens:",
"        <ul>",
"         <li>",
"          Cancer and Leukemia Group B (CALGB study 8811 or 9111) ALL regimen",
"          <sup>",
"           [1,2]",
"          </sup>",
"         </li>",
"         <li>",
"          Hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD) alternating with high-dose methotrexate and cytarabine",
"          <sup>",
"           [3]",
"          </sup>",
"         </li>",
"         <li>",
"          French GRAALL-2003 regimen",
"          <sup>",
"           [4]",
"          </sup>",
"         </li>",
"         <li>",
"          German GMALL protocols 06/99 and 7/03",
"          <sup>",
"           [5]",
"          </sup>",
"         </li>",
"        </ul>",
"        <br/>",
"        The combination of a TKI with or without a corticosteroid is capable of producing complete remissions in previously untreated Ph+ ALL with low toxicity",
"        <sup>",
"         [6]",
"        </sup>",
"        . This combination has not been directly compared with a TKI plus chemotherapy. If initial data are supported by subsequent studies, the combination of a TKI plus steroid may become an excellent option for patients, such as older adults, who are not able to tolerate combination chemotherapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Consolidation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allogeneic hematopoietic cell transplantation in first complete remission is preferred. If the patient is not a candidate for transplantation, consolidation chemotherapy should be given that incorporates a BCR-ABL TKI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A BCR-ABL TKI for two years after allogeneic hematopoietic cell transplantation or indefinitely if a transplantation is not performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serial bone marrow evaluation and minimal residual disease testing with BCR-ABL transcripts using real time quantitative polymerase chain reaction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: The BCR-ABL TKI chosen should be consistent with the BCR-ABL tyrosine kinase used in the specific treatment protocol.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85:2025.",
"       </li>",
"       <li>",
"        Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92:1556.",
"       </li>",
"       <li>",
"        Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116:2070.",
"       </li>",
"       <li>",
"        Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911.",
"       </li>",
"       <li>",
"        Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108:1469.",
"       </li>",
"       <li>",
"        Fo&agrave; R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118:6521.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41740=[""].join("\n");
var outline_f40_48_41740=null;
var title_f40_48_41741="Estimates of energy requirements for children";
var content_f40_48_41741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimates of energy requirements (kcal/day) for healthy children with moderate physical activity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        WHO estimates* (kcal/kg/day)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        IOM estimates",
"        <sup>",
"         &bull;",
"        </sup>",
"        (kcal/kg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Boys",
"       </td>",
"       <td class=\"subtitle2\">",
"        Girls",
"       </td>",
"       <td class=\"subtitle2\">",
"        Boys",
"       </td>",
"       <td class=\"subtitle2\">",
"        Girls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 months",
"       </td>",
"       <td class=\"centered\">",
"        82",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24 months",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 4 years",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        104",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 5 years",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 to 6 years",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        72",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 7 years",
"       </td>",
"       <td class=\"centered\">",
"        73",
"       </td>",
"       <td class=\"centered\">",
"        69",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 8 years",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 to 9 years",
"       </td>",
"       <td class=\"centered\">",
"        69",
"       </td>",
"       <td class=\"centered\">",
"        64",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 to 10 years",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"       <td class=\"centered\">",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 to 11 years",
"       </td>",
"       <td class=\"centered\">",
"        65",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11 to 12 years",
"       </td>",
"       <td class=\"centered\">",
"        62",
"       </td>",
"       <td class=\"centered\">",
"        55",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 to 13 years",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 to 14 years",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        49",
"       </td>",
"       <td class=\"centered\">",
"        57",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14 to 15 years",
"       </td>",
"       <td class=\"centered\">",
"        56",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"       <td class=\"centered\">",
"        55",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 to 16 years",
"       </td>",
"       <td class=\"centered\">",
"        53",
"       </td>",
"       <td class=\"centered\">",
"        45",
"       </td>",
"       <td class=\"centered\">",
"        54",
"       </td>",
"       <td class=\"centered\">",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16 to 17 years",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"       <td class=\"centered\">",
"        44",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"       <td class=\"centered\">",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17 to 18 years",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        44",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        43",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization; IOM: Institute of Medicine.",
"     <br>",
"      * The WHO estimates are based on assumed physical activity levels of 1.45 to 1.85 mJ/day (boys, increasing with age), and 1.4 to 1.7 mJ/day (girls, increasing with age), considered \"moderate physical activity\" (rather than light or vigorous physical activity).",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       The IOM estimates for children 3 to 18 years are based on assumed physical activity coefficients of 1.6 to 1.9 mJ/day, considered \"active\" (rather than sedentary, low active, or very active).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        WHO estimates from: Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO) and United Nations University (UNU): Human Energy Requirements. Chapter 4: Energy requirements of children and adolescents. Available at: file://www.fao.org/docrep/007/y5686e/y5686e06.htm#TopOfPage (Accessed on January 21, 2013).",
"       </li>",
"       <li>",
"        IOM estimates from: DIETARY REFERENCE INTAKES FOR ENERGY, Institute of Medicine, 2005. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients), 2005, chapter 5. Available at: file://fnic.nal.usda.gov/dietary-guidance/dri-reports/energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino#overlay-context=dietary-guidance/dietary-reference-intakes/dri-reports (Accessed on January 21, 2013).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41741=[""].join("\n");
var outline_f40_48_41741=null;
var title_f40_48_41742="Types of DILI";
var content_f40_48_41742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of drug-induced liver injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acute injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hepatocellular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acarbose",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acetaminophen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Allopurinol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Buproprion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bromfenac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diclofenac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fluoxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Halothane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ketoconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lisinopril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Losartan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Methyl-dopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nefazodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nevirapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Paroxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pyrazinamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rifampin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Risperidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ritonavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sertraline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Statins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trazodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thiazolidinediones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trovafloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valacyclovir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valproate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cholestasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            ACE inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amoxicillin/Clavulanate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anabolic Steroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Azathioprine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chlorpromazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Clopidogrel",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Erythromycins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Estrogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Irbesartan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sulindac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Terbinafine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tricyclics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mixed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amitryptilline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Azathioprine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Captopril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Clindamycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cyproheptadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Enalapril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Flutamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ibuprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nitrofurantoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenobarbital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trazodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Verapamil",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Chronic injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Steatohepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amiodarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valproic Acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Microvesicular steatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            NRTIs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valproic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Granulomatous hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Allopurinol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diltiazem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hydralazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Penicillamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quinidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rosiglitazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Sinusoidal obstruction syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Busulfan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cyclophosphamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Imuran",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Methyldopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Peliosis hepatis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anabolic steroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vinyl chloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Autoimmune hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nitrofurantoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Minocycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Statins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Chronic hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diclofenac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Methyldopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Minocycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nitrofurantoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trazodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Neoplasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anabolic steroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vinyl chloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ischemic necrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ergot",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NRTIs: nucleoside reverse transcriptase inhibitors.",
"     <br>",
"      Sinusoidal obstruction syndrome (SOS): previously called veno-occlusive disease (VOD).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and expanded from: Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25:1135.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41742=[""].join("\n");
var outline_f40_48_41742=null;
var title_f40_48_41743="Shoulder arthrocentesis";
var content_f40_48_41743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shoulder arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the shoulder externally rotated, the needle is inserted at a point just medial to the head of the humerus and slightly inferior and lateral to the coracoid process. The needle is then directed posteriorly and slightly superiorly and laterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_48_41743=[""].join("\n");
var outline_f40_48_41743=null;
